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Abstract 
Young women are diagnosed with breast cancer; and young women die from breast can-
cer. This qualitative dissertation seeks to prove the significance of lowering the mammography 
age from 40 years old to 30 years old. Current policy and programs correlate to the mandated age 
of 40 years old, unless the woman is at high risk; such as having a family cancer history. This 
dissertation also seeks to implement an addendum to insurance policies to cover for younger 
women to have mammography screening in the event they are younger than the recommended 
age. The purpose of this study was to examine policy frameworks of screening mammography’s 
and insurance coverage.  
This qualitative dissertation will examine what are women’s early experiences with their 
medical providers who have been diagnosed with breast cancer; and are there components of the 
women’s early experiences that served as barriers to them getting treatment I recommend women 
who are 30 years of age having mammography screenings, women being taught how to perform 
self-examinations, and educate women how to decrease their risk of developing breast cancer. 
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Chapter One: Introduction 
 The impact of mammograms on treatment options, patient survival and patient trajectory 
continues to be a debate in public policy. Screening recommendations according to The Ameri-
can Cancer Society (ACS), The National Comprehensive Cancer Network (NCCN), and The 
U.S. Preventive Services Task Force (USPSTF)  recommend women having mammogram 
screening starting at the age of 40 years old, unless they are at high risk (Susan G. Komen, 
2020). Other recommendations state depending on family history and the results of the initial 
mammogram, women can have mammograms performed every two years, instead of annually. 
Mammography screening offers detection for a breast cancer diagnosis. Patient care and survival 
outcomes are related to the use, and timing, of 3D mammography screenings. This dissertation 
considers the experiences of women who have been diagnosed with Triple Negative Breast Can-
cer (TNBC), and other types of  breast cancer in the context of existing policies, and will make 
policy and program recommendations that may also be able to improve patient care and survival 
outcomes. In this chapter we will review the problem statement, purpose of study, significance of 
study/rationale, research questions and summary. 
Problem Statement 
 Mammogram screening policy needs to be updated to represent women who are diag-
nosed younger than the age of 40 years old.  There are shortcomings in care due to insurance 
policies and treatment protocols. In clinical practice and relevant research, women who have 
been diagnosed under 40 years old have higher mortality rates. The problem may be that medical 
providers are not in routine of the discipline of women’s health protocols; therefore, women are 
not set up to get treatment as early as possible. General women’s healthcare practice guidelines  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do not include breast care/breast health screening early enough to help detect aggressive forms of 
breast cancer in young women. 
 Women’s early experiences with their medical providers predicts the trajectory of their 
breast cancer treatment. The potential barriers that are present before and after diagnosis are ac-
cess to screening age, healthcare/health insurance, financial responsibility, familial responsibility, 
distrust and education. All these factors play a role in the access to treatment once a woman is 
diagnosed with breast cancer.  
 After the breast cancer diagnosis, the woman and her provider, need to determine and 
agree, whether she will have the tumor removed (lumpectomy), a portion of her breast removed 
(segmental mastectomy), her affected breast removed (mastectomy), or both breasts removed 
(double mastectomy). In addition, several lymph nodes will be taken out to determine the extent 
of the breast cancer, which can result in lymphedema—which can be manipulated with physical 
therapy. The woman needs to decide who will help her through this process, and during the re-
covery stages. Women typically must have chemotherapy to kill the cancerous cells, which result 
in hair loss, neuropathy (more than likely), fatigue, weight loss or gain (steroid), possible nausea, 
and a host of other side effects. Radiation therapy may be needed to be utilized for local control, 
and to kill any cancerous cells that are microscopic. Immunotherapy may be used which helps 
the woman’s healthy cells combat the cancerous cells. If a woman is diagnosed with estrogen 
receptor breast cancer then she will be placed on an estrogen receptor blocker, which she would 
have to take for 5 to 10 years. In all of this, the woman is still a person. She is a mom, wife, sis-
ter, friend, cousin, worker, confidant, and so much more. She must carry the diagnosis, but also 
other things that life offers because life does not stop because of a cancer diagnosis. 
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 Although eradicating breast cancer may not be plausible due to genetics and environmen-
tal factors, the goal ought to be catching the disease in its infancy stage; so that when women are 
diagnosed with breast cancer, it is manageable and curable. JamRiv, who is also a metastatic 
cancer survivor, says she wants breast cancer to turn out the way HIV/AIDS and diabetes is. In 
the 1980s, HIV/AIDS was a death sentence to the millions of people that contracted it. Now, if 
diagnosed, the disease is manageable, and millions of people live healthy, manageable lives. 
Similarly, with millions of people with diabetes—it can be controlled. For JamRiv, that is the 
goal of breast cancer. To hopefully discover a blood test, that can detect if a woman has breast 
cancer. The goal is to kill the breast cancer in its infancy and to monitor the women who have/
had breast cancer and give them the tools to look out for changes in their health pre and post 
treatments. By doing so millions of lives can be saved, and breast cancer will be manageable. 
Purpose of Study 
 The purpose of this qualitative dissertation is to examine what are women’s early experi-
ences with their medical providers; and to determine if there are barriers in the initial contact 
with their medical providers. The purpose is also to determine if that initial contact prevented 
them from seeking diagnostic screening prior to their diagnosis, and to the access and timing of 
treatment. Women are not getting screened early enough, and they are dying of breast cancer. Al-
though research has shown a small (in comparison) number of young women being diagnosed 
with breast cancer, there is still little research that has been done to understand the barriers to 
screening; or the factors that lead to delayed diagnosis.  
 The goal is to educate women regarding breast health and breast cancer. Developing poli-
cies and programs should include breast health education, in addition to giving women the nec-
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essary information regarding breast lumps, breast density, 3D mammograms, family cancer his-
tory and genetic counseling. In the next section, this qualitative dissertation will aim to fill the 
gap of knowledge by providing an in-depth examination of a sample of women’s early experi-
ences that navigates their breast cancer diagnosis. This qualitative dissertation will provide in-
formation on how to redesign policy and programs to have better outcomes such as early mam-
mography screening, insurance approval/coverage and women’s early experiences with their 
medical providers.  
Significance of Study/Rationale 
 The significance of this qualitative dissertation is to determine ways to refine and im-
prove federal policies and healthcare programs in order to: short term goal, uncover more details 
about women’s early experience with breast cancer; long term goal, save the lives of women who 
are diagnosed with breast cancer. In terms of public policy, The American Cancer Society (ACS), 
The National Comprehensive Cancer Network (NCCN), and The U.S. Preventive Services Task 
Force (USPSTF) have recommended that starting at the age of 40 years old women should have 
annual mammography’s. States therefore are mandated to cover women’s mammography’s start-
ing at the age of 40 years old whether they have insurance or not; therefore increasing mammo-
gram utilization. The issue is there needs to be an addendum to the guidelines for women less 
than 40 years of age due to certain risk factors, such as genetics and family history. This qualita-
tive dissertation aims to research if there are gaps, in regard to women’s awareness, patient-
provider relationship, if recommendations need to be amended, insurance protocols should 
change, and screening guidelines should alter. 
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 The suspected problem is women are experiencing barriers in their early experiences with 
their medical providers, therefore creating a barrier to their access to early treatment. Finding 
potential gaps and preventing the barriers will make the trajectory of breast cancer manageable. 
Screening 3D mammography improves breast cancer survival through early detection (Chen, et. 
al.,2020, p. E1). Younger women are more likely to have higher-stage and higher-grade disease, 
and their tumors were more likely to be triple negative (Partridge, et. al.,2016, p. 3). Women less 
than 40 years old were 90% more likely to die of breast cancer than were women ages 51 to 60 
years at diagnosis (Partridge, et. al.,2016, p. 3). Young women, on average, have an increased 
risk of disease recurrence and decreased survival; also, young age at diagnosis has long been 
considered a poor prognostic factor (Partridge, et. al.,2016, p. 3). A potential barrier begins with 
breast health. 
 Breast health is simply women knowing their bodies and knowing what her breasts feel 
like and look like. What is included in breast health is knowing the difference between what the 
breasts look and feel like before, after, and during menses. The term also includes what women 
put into their bodies; such as, eating healthy, eating balanced meals, not smoking, exercising, 
achieving a health body weight, and reducing the consumption of alcoholic and sugary drinks. It 
is also equally important that women breastfeed after birth (Helen F. Graham Community Advi-
sory Board, 2019). Additionally, breast health encompasses knowing the family history of breast 
cancer and other cancers in the family—on both the maternal and paternal side. High-risk 
women include those with a strong family history of the disease (Guo, Kuo, Shih, Giordano 
&Berenson, 2018, p. 3500). This is important because depending upon the family history, may 
increase the likelihood of the woman being diagnosed with breast cancer. It is also important to 
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know who had the cancer, what type of cancer, and at what age the family member was diag-
nosed (Helen F. Graham Community Advisory Board, 2019). All this information is crucial in the 
screening process, and in the early experiences. Without this information women risk the chance 
of developing breast cancer. 
 It is important that women talk with her healthcare provider, such as her primary care 
doctor, or gynecologist, and discuss screening recommendations regarding when they should 
have a clinical breast exam, an ultrasound, mammogram, and/or MRI performed to detect or rule 
out cancer. Depending upon the woman’s history, clinical breast exams, and the other diagnostic 
tools that were described above, could be utilized every six months, as well as, annually. One of 
the other potential barriers is education.  
 Education is the steppingstone to eliminate barriers. Women with Medicaid and no insur-
ance are less likely to have a primary medical doctor. There is lack of knowledge of general 
breast cancer prevention strategies (Sims-Mourtada, et. al., 2019, p.e2). They are also less likely 
to have screening 3D mammograms and have a based line of breast health. Research has found 
women without insurance are 60% more likely to die from breast cancer compared to women 
who have insurance. Kimberly Johnson, an epidemiology professor at Washington University 
stated that improving medical care and diagnostic screening can change the trajectory of cancer 
outcomes. Educated women will able to advocate for their breast health, but not all women do 
just that. A myriad of women, especially young women have fibrocystic breasts, which makes 
the breasts feel “bumpy," and therefore, may ignore the feel of a lump because of previous clini-
cal presentation.  
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 In addition, there are some potential barriers to access of healthcare. Many women who 
are part of a low socioeconomic class may not have access to a primary care doctor or gynecolo-
gist; therefore, their health is hindered. This particular group of women may not have insurance 
which prevents them from seeing a healthcare provider because of out-of-pocket costs. Addition-
ally, having Medicaid, could limit certain resources of having a medical provider, and the types 
of services that are included in the insurance package. Belonging to that class could also mean 
not fully understanding breast health and the ramifications of delaying treatment. This is not to 
say that women part of a higher class does not ignore signs and symptoms of breast health, or 
completely understand breast health; it does mean that statistically those who are in the lower 
socioeconomic class experiences are different, and arguably harder. The results confirm that 
mandating insurance coverage for low-cost preventative health services can meaningfully in-
crease utilization rates (Bitler and Carpenter, 2016, p. 2). If insurance will cover the cost of diag-
nostic tools, then research shows women would get the diagnostic testing done.  
 There is also the notion that women, as a group, regardless of race or ethnicity, are seen 
as strong beings and simply ignore their body signs because they are taking care of their families 
and others; and unfortunately, by the time their bodies make them listen, it is often too late. His-
torically, women place themselves on the back burner to ensure everyone else’s health and safety, 
but unfortunately to the detriment of themselves. Women typically always “push through” and 
make themselves the last priority. This is another barrier that needs to cease. This barrier is creat-
ed by society and women themselves. There is nothing wrong with taking care of others, and 
self, but when the body gives a sign, it is up to the woman to listen. If not, she cannot take care 
of others, or help others, if her body is not cooperating or healthy. Given the demonstrated effi-
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cacy of endocrine therapy in reducing the risk of recurrence and death among women with lumi-
nal disease, adherence in this population is a critical issue that needs to be addressed (Partridge, 
A. H.,et. al.,2016, p. 6). It is researched that even when women are diagnosed with breast cancer, 
they still have the task of taking care of others; therefore, delaying (in some way) their treat-
ments. Other women may not know their family history to the extent, and accuracy as they 
should. 
 Some women are also only concerned with their maternal side of medical information, 
and do not understand the paternal medical information is just as important to know for breast 
health. Depending on the family history and the density of cancer diagnoses, genetic testing 
might be offered to the young woman; therefore, determining the likelihood of her developing 
certain cancers such as: breast, cervical and ovarian. With that specific information, a woman is 
given the autonomy to determine what she wants to do with her body and reproductive system. 
Once a woman has children, or decides she does not want children, or physically bare the chil-
dren; she may opt to have not only a mastectomy/breast removal (single or double), but also a 
total hysterectomy—to lower the incidence of developing cancer.  
 Genetic testing can be performed before a cancer diagnosis or after the initial diagnosis. 
The importance of genetic testing is for health and abundant knowledge. Also, genetic testing is 
not just for the woman who is being tested, but for her family as well. Based on their tumor type 
and the molecular characteristics, genetic testing in young patients with cancer also enables them 
to receive tailored treatments (Guo, et. al., 2018, p. 3506). If she knows she is a BRCA1 or BR-
CA2 carrier, for example, then that information is needed for what she needs to do for her health, 
but also what her children, mother, sisters, cousins, etc., need to do for their health as well.  
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 Younger women are more likely to harbor a BRCA1, BRCA2, or other cancer-related ge-
netic-associated tumor (Partridge, A. H.,et. al.,2016, p. 6). This type of information will also al-
low insurance companies (private, Medicare, Medicaid, no insurance) to pay for certain screen-
ings and procedures. If a woman does not have insurance, grants can be provided. There are al-
ways financial resources for women in need. The questions are: What are women’s early experi-
ences with their medical providers who have been diagnosed with breast cancer? Are there com-
ponents of women’s early experiences that served as barriers to getting treatment? The potential 
barriers that are being investigated are lack of knowledge and education, insurance, and fear. 
Women’s early experiences with their medical providers, doctors, vary, and their experiences can 
either help or hinder their access to screening and treatment. 
 There are some types of breast cancers that are more advanced than others, such as in situ 
breast cancer versus inflammatory breast cancer. In situ breast cancer has a better prognosis than 
inflammatory breast cancer. The point is, to an extent, once any breast cancer is caught early, it is 
more manageable. Women then can live healthier and better lives because their quality of life has 
shifted.  
Research Questions 
• What are women’s early experiences with their medical providers who have been di-
agnosed with breast cancer? 




 My qualitative dissertation questions are: What are women’s early experiences with their 
medical providers who have been diagnosed with breast cancer? Are there components of their 
early experiences that served as barriers to getting treatment? The questions will be answered in 
the depth and explain why this is not just a woman’s issue, but a problem for humanity. 
 This qualitative dissertation is organized by five chapters. Chapter One is the introduction 
which introduces the issues faced by women who have breast cancer who are less than the age of 
40. Chapter Two is the Literature Review and backs up the information that woman under 40 
years old are being diagnosed with breast cancer and outlines the barriers to their access to 
treatment and preventative care. Chapter Three outlines the Research Design and Methods which 
describe the qualitative interview methods which were obtain by breast cancer survivors and dis-
cussed their stories. Chapter Four concludes the Research and Findings which are the main 
themes which were found through the collection of interviews. Chapter Five are given Recom-
mendations for policies and public recommendations.  
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Chapter Two: Literature Review 
 What are women’s early experiences with their medical providers who have been diag-
nosed with breast cancer? Are there components of their early experiences that served as barriers 
to getting treatment? This chapter will seek to explain the significance and purpose of these pro-
posed questions. In this chapter, public policy, types of breast cancer, incidence and prevalence 
of breast cancer, risks that are associated with breast cancer, potential barriers that prevent 
women from accessing treatment, and screening/policy recommendations are discussed.  
Public Policy 
 The public policy implications of this study in general and specifically with respect to the 
federal health reform is simple, if a greater scientific consensus were to be reached regarding the 
more appropriate screening frequencies for women of difference ages, policies could be amended 
accordingly (Bitler & Carpenter, 2016, p. 21). Mandating diagnostic mammogram screening at 
little to no out-of-pocket cost would prevent potential barriers or gaps to women receiving care 
and treatment. In order for this to happen the rational goal model can be used, which incorporates 
goal setting and attainment, and productivity and efficiency (Tompkins, 2005, p. 28). By setting a 
goal that women should be covered regardless of their age if they need diagnostic mammogram, 
attainment can be monitored, and aspects of productivity can be utilized. Efficiency will be de-
termined by how many young women had a breast health concern, and were able to receive a di-
agnostic mammogram, that was covered, by insurance.  
 Ethically, it is the duty of the medical professionals to see that women are being screened 
of breast cancer regardless of their age or insurance coverage. Denhardt, Denhardt, and Blanc 
(2014) define ethics as “the process by which we clarify what is right and wrong and by which 
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we act on what we take to be right; it involves the use of reason in determining a proper course 
of action” (p. 150). What is right is to use the tool of mammography as intended, to detect can-
cer. The proper course of action should require a woman, regardless of status, to have the screen-
ing if truly needed. This is the concept of equity. That regardless of the woman’s status, she is 
still able to receive a diagnostic mammogram. “Social equity further recognizes the importance 
of public servants and public sector organizations in fulfilling the democratic principle of fair-
ness” (Guy and Rubin, 2015, p. 212). Younger women receiving diagnostic mammograms is fair, 
is equitable. The patient-provider relationship is also important for the woman to receive the 
mammogram screening. 
 Every patient-provider relationship is different. There are also different types of patient-
provider relationship, the first is paternalistic. The paternalistic model, the provider is very active 
and directive; this person is often seen as the expert, and thus, patients often follow the recom-
mendations (Kelly, et. al., 2019, p. 104). The approach is very direct, and maybe useful in the 
relationship where the patient is very unattached and needs direction and guidance. The second 
approach is the informative model. The informative model, the provider is more passive; the 
physician provides the patient with all the information and options, often serving as an educator, 
while waiting for the patient to decide (Kelly, et. al., 2019, p. 104). The provider allows the pa-
tient to determine what the patient wants. The third model, interpretive model, enables the 
providers to take an advising position to help patients understand their values and give patients 
the information they need to facilitate decision-making for the patient (Kelly, et. al., 2019, p. 
104). The last model is the deliberative model. It is characterized by the patient and provider 
openly engaging in a mutual discussion of treatment options and exploration of the patients 
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moral and value systems associated with treatment (Kelly, et. al., 2019, p. 104). This allows the 
patient to have more autonomy regarding how they want to proceed with treatment. In other 
words, the paternalistic model is low in information giving, high in provider involvement; infor-
mative is high information giving, low provider involvement; interpretive is high information 
giving, high provider involvement; and deliberative is low information giving, low provider in-
volvement (Kelly, et. al., 2019, p. 104). 
 Some patients come to the provider with a slew of information and the bulk of the re-
sponsibility is not on the provider. On the other hand, there are situations where the provider 
takes on a role for both the patient and provider due to the lack of knowledge that the patient has 
coming in regarding their breast care. Patients often view their medical provider as an “expert” in 
medical knowledge with the skills to extend the quality and quantity of their life (Kelly, et. al., 
2019, p. 101). Yet, providers may often assume the patients want the autonomy of their care. It is 
important to adapt the clinical relationship in a way that is most comfortable and engaging for 
the individual patient rather than generalizing the patient role or “standardizing” every patient-
provider relationship (Kelly, et. al., 2019, p. 101). Overall patients with secure attachment had a 
better working alliance with their physician and perceived more support from their provider than 
patients with an insecure attachment (Kelly, et. al., 2019, p. 104). 
 The attachment theory is important to note because it shows the importance of the pa-
tient-provider theory. This theory is also vital because as explained in Chapter 3, the patients’ 
experiences were based on, in many ways, this theory. 
Types of Breast Cancer 
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 The most common types of Breast Cancer are Ductal Carcinoma In-situ (DCIS), Triple 
Negative Breast Cancer (TNBC), Inflammatory Carcinoma, Infiltrating Carcinoma, Metastatic 
Breast Cancer (MBC), and Invasive Ductal Carcinoma (National Breast Cancer Foundation, 
Inc. ,2019). The least common types of Breast Cancer are Medullary Carcinoma, Tubular Carci-
noma, Mucinous Carcinoma (Colloid), and Paget Disease of the Breast or Nipple or also known 
as Mammary Paget Disease. (N.,2019). Breast cancer is not the same in every woman, and re-
acts, and is different in each woman. How many women are diagnosed with breast cancer, and at 
what rate are they being diagnosed is to be explained. 
 Incidence and Prevalence  
 Breast cancer is the second leading cause of death for women in the United States. “The 
incidence rate for female breast cancer in the United States from 2010 to 2014 was 123.6 per 
100000 population” (Sisti A, Huayllani MT, Boczar D, et al., 2020, p. 1). “A total of 2,423,875 
women were diagnosed with breast cancer between 2004 and 2015. 136,525 breast cancer pa-
tients (5.6%) were less than 40 years old (Sisti A, Huayllani MT, Boczar D, et al., 2020, p. 3). 
The predominant race was white (2022918 patients, 84.3%), followed by black (271401 patients, 
11.3%), Asian (6138 patients, 0.2%), Native American (78535 patients, 3.2%) and other (18256 
patients, 0.7%) (Sisti A, Huayllani MT, Boczar D, et al., 2020, p. 3). The average number of days 
between the date of diagnosis and the date on which the most definitive surgical procedure was 
performed on the primary site was 51 (Sisti A, Huayllani MT, Boczar D, et al., 2020, p. 3). With 
respect to stage, 486,856 (20.88%) patients corresponded to Stage 0, 961981 (41.27%) patients 
to Stage I, 587352 (25.20%) patients to Stage II, 203159 (8.71%) patients to Stage III, 91864 
(3.94%) patients to Stage IV (Sisti A, Huayllani MT, Boczar D, et al., 2020, p. 4). Women are 
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being diagnosed with breast cancer at alarming rates. Early detection, and screening mammogra-
phy is needed to detect that cancers in the women’s breasts. 
 Broadly, invasive characteristics were noted more frequently in younger patients ; the 
presence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the 
primary tumor was noted more frequently in younger patients, as well as a higher grade at diag-
nosis (Sisti A, Huayllani MT, Boczar D, et al., 2020, p. 6). As described, young women are being 
diagnosed with advanced breast cancer, and there is certain risk that increase their chances of de-
veloping the disease.  
Risks 
 The following are risks that increases women’s chances of developing breast cancer—
race, age, family cancer history, genes, menstrual status, oral contraceptive use, birth history, 
lack of education, age of first and last birth, and maternal smoking. All these risks increase the 
incidence, and in some cases, the mortality of women being diagnosed with breast cancer. There 
has not been enough research on investigating how women’s awareness of their risk relates to the 
timing of their screening. This qualitative study will aim to fill that gap.  
Race 
 Race is a risk factor when it comes to breast cancer. African American women have a 
higher prevalence of being diagnosed and dying from Triple Negative Breast Cancer (TNBC). 
Just being African American can put a woman at a higher risk than other races. There is a con-
cept that is being researched by Dr. Lisa Neumann determining which country in Africa predis-
poses women to Triple Negative Breast Cancer. The issue arises that African American women 
typically do not know their country of origin, hints the blanket and broad name of African Amer-
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ican. The term African American just means that, in this case, the women do not know which 
country they derive from in that continent. Dr. Neumann’s research shows that women that de-
rive from Ethiopia typically have a lower chance of being diagnosed with TNBC, compared to 
women who’s origin stems from Nigeria. Black women are also most likely to be diagnosed with 
tumors that are ≥5.0 cm (12%) or high grade (42%) (DeSantis, et. al., 2019, p. 441). 
  Moreover, black women are the only group for which high-grade tumors are more com-
mon than low-grade or intermediate-grade tumors (DeSantis, et. al., 2019, p. 441). Likewise, 8% 
of black patients with breast cancer are diagnosed with distant-stage (metastatic) breast cancer 
compared with 5% to 6% of patients of other races/ethnicities. (DeSantis, et. al., 2019, p. 441). 
 Black-white disparities in breast cancer incidence and mortality are largest in young 
women and decline with age. Black women have the highest breast cancer incidence rate before 
age 40 years and are most likely to die from breast cancer at every age. (DeSantis, et. al., 2019, 
p. 442). According to DeSantis, et. al. (2019) “Approximately 19% of breast cancers diagnosed 
in black women are HR-negative/HER2-negative (triple negative) compared with 11% in His-
panics, 9% in whites, 6% in APIs, and 5% in AIANs” (p. 441). One of the most evident informa-
tion was not just age, but race. “Breast cancer incidence rates are highest in whites (130.8 per 
100,000), followed closely by blacks (126.7 per 100,000), and are lowest in APIs (93.2 per 
100,000); however, black women have the highest breast cancer death rate (28.4 per 100,000), 
which is 40% higher than the rate in white women (20.3 per 100,000) and more than double the 
rate in API women (11.5 per 100,000)” (DeSantis, et. al., 2019, p. 442). Also, Black women are 
more likely to be screened at lower resourced and non-accredited facilities and to experience 
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longer intervals between screening mammograms and between abnormal findings and follow-up. 
(DeSantis, et. al., 2019, p. 445). 
 According to Chen, Y., et. al., (2020), “Population-based breast cancer mortality is 40% 
higher among African American women compared with Caucasian American women, a disparity 
partly explained by 2-fold higher incidence of biologically aggressive triple negative breast can-
cer (TNBC) in African American women” (p. E1). What is especially true for young black 
women is that incidence rates of invasive breast cancers in African Americans (AA) are rising 
(0.9%/year 2005-2014). (Sims-Mourtada.,et. al., 2019, p. e1). This may be attributed to the fact 
that Black women younger than 40 years experienced the largest increase in mean body mass 
index (BMI) compared to white women over the same period (Sims-Mourtada,et. al., 2019, p. 
e1). Another potential risk factor is the age of the woman. There has not been enough research on 
investigating how women’s awareness of their risk relates to the timing of their screening. This 
qualitative study will aim to fill that gap. 
Age 
 Age can be a risk factor for women being diagnosed with breast cancer. Typically, 
women who are diagnosed under 40 years old have a higher stage of breast cancer; therefore, in 
some cases lessening their chance of survival. 
  Breast cancer is typically overlooked in young women [women less than 35 years old]. 
In a study performed in Norway, it was looked at as to why young women are being diagnosed 
with breast cancer—Breast Cancer Incidence before Age 55 in Relation to Parity and Age at 
First and Last Births: A Prospective Study of One Million Norwegian Women. The idea is simply, 
young women can be diagnosed with breast cancer, too. Therefore, when young women are di-
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agnosed with breast cancer, their children and relatives are often screened at an even younger 
age. For example, if a woman is diagnosed with breast cancer at the age of 35, then her daughter 
needs to start having diagnostic screenings performed at the age of 25. There has not been 
enough research on investigating how women’s awareness of their risk relates to the timing of 
their screening. This qualitative study will aim to fill that gap. 
Family Cancer History 
 Family cancer history is very important. For women, it is important to know who in their 
family had or has cancer, at what age they were diagnosed, and what type of cancer he or she had 
or has. This information determines the risk or likelihood of the woman being diagnosed with 
cancer. For example, if a woman’s mother was diagnosed with breast cancer at 40 years old, the 
daughter and some clinicians would even recommend the son, to have a yearly baseline clinical 
breast exam at the age of 30; including a mammogram depending upon the type of cancer and 
other family history that the mother has. All this information is very much important because it 
can save the woman’s life, and additionally if this medical issue is documented, it can be possible 
for a person’s insurance to cover the screening. There has not been enough research on investi-
gating how women’s awareness of their risk relates to the timing of their screening. This qualita-
tive study will aim to fill that gap. 
Genes 
 There are genes that women must be aware of that can increase their incidence rate of 
being diagnosed with breast cancer. The young women who are being diagnosed with breast can-
cer in their younger years, it is being attributed to their mutated genes that they have received 
from their mother or father, as their donors. Therefore, women who are diagnosed with breast 
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cancer, especially at a young age should have genetic testing done to determine their risk of de-
veloping breast cancer. If a woman turns out to have the genes, such as BRCA 1 and 2, then her 
children, boy or girl, need to be screened for breast cancer, and other cancers, at an early age. 
 According to DeSantis, et. al. (2019) “A recent study reported that the prevalence of the 
triple-negative subtype in black women in the United States varied substantially by country of 
birth; compared with US-born blacks, the prevalence was 47% lower in women born in countries 
in Eastern Africa but only 8% lower in Western Africa-born blacks. In another study of women in 
California, those of Korean, Filipina, Chinese, and Southeast Asian descent had a higher risk of 
HER2-positive breast cancers compared with white women, whereas those of Japanese and 
Asian Indian descent had a lower risk. Differences in breast cancer subtype within and between 
racial/ethnic groups likely reflect variations in the prevalence of breast cancer risk factors and 
mammography use, but may also be related to genetic variations” p. 443. 
 Genetics play a potential role in the risk of breast cancer. Menstrual status also may play 
a role in the potential risk of developing the disease. There has not been enough research on in-
vestigating how women’s awareness of their risk relates to the timing of their screening. This 
qualitative study will aim to fill that gap. 
Menstrual Status 
 It is noted and has been researched that woman who had their menstrual early on have a 
higher incidence of being diagnosed with breast cancer. Women who developed breast cancer 
were more likely to have short, regular cycles, and had more cycles before the first full-term 
pregnancy than healthy women and those with benign breast disease (Olsson & Olsson, 2020, p. 
1). Though it is not yet understood why. One of the theories is that cell division is generally con-
sidered a prerequisite for carcinogenesis and women with short and numerous cycles may there-
fore have a higher risk of developing cancer as a result of increased cell proliferation (Olsson, et 
al., 2020, p. 1). Researchers are determining that a high number to menstrual cycles, and men-
strual activity increases breast cancer risk for women (Olsson, et al., 2020, p. 1). Though the 
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concept of menstruation status is being keenly researched as a risk of breast cancer, it is known 
that it can be a potential risk and should be noted and reviewed; as well as the use of birth control 
or oral contraception. There has not been enough research on investigating how women’s aware-
ness of their risk relates to the timing of their screening. This qualitative study will aim to fill 
that gap. 
Oral Contraceptive Use 
 The theory is that oral conception use can increase the risk of breast cancer diagnosis is 
women. Researchers noted that women were diagnosed 5 years prior with oral contraceptive use, 
who were less than 35 years old. There has not been enough research on investigating how 
women’s awareness of their risk relates to the timing of their screening. This qualitative study 
will aim to fill that gap. 
Health 
 An unhealthy lifestyle can increase the risk of breast cancer. Eating unhealthy foods, 
smoking, drinking alcohol, and not exercising, unfortunately increases the risk. “Maintaining a 
healthy body weight, increasing physical activity, eating a nutritious diet, avoid smoking and re-
ducing alcohol consumption may be helpful to mitigate increasing breast cancer incidence in 
African Americans” (Sims-Mourtada,et. al., 2019, p. e1). Keeping the body at a healthy state, 
decreases the risk of the disease. Eating a healthy diet decreases the risk of breast cancer. Drink-
ing more water and drinking less of alcohol and drinks with a lot of sugar decreases cancer. 
Avoiding smoking also decreases the risk. All these factors reduce the risk of developing breast 
cancer. There has not been enough research on investigating how women’s awareness of their 
risk relates to the timing of their breast screening. This qualitative study will aim to fill that gap. 
  !20
Age of First and Last Birth 
 Research states when women give birth at a young age, or have children later in life, that 
increases their incidence of breast cancer (Chakravarthi & Varambally, 2013, p.1). Also, women 
who gave birth between the ages of 20 to 24 had an increase risk. To clarify, if a woman gives 
birth in her early 20s, or gives birth in her late 40s, both scenarios increases her risk of develop-
ing breast cancer. These researchers are correlating at what age women were when they had their 
first full term birth, and last term birth; and how many children did they have total. All this in-
formation plays a role in the breast cancer diagnosis. From their research, women from the age of 
20 years old, and from the time a woman delivered her first child, was at risk for developing 
breast cancer. This mean if a woman starts birthing her child or children starting at the age to 20, 
she increases her risk of developing breast cancer. With that information young women have a 
greater incidence of tumors, primary tumors, being in the ovaries. There has not been enough 
research on investigating how women’s awareness of their risk relates to the timing of their 
screening. This qualitative study will aim to fill that gap. 
Maternal Smoking 
 There was also an increased risk in maternal smoking among women 30 years and 
younger. There is an interesting realization if the hypothesis is proven to be sound. When women 
smoke during puberty, they are essentially negatively affecting their genetic make-up; therefore, 
increasing their incidence of breast cancer. Also, when women smoke during puberty they are 
also affecting the fetal tissue, which is being exposed to cancer cells; hypothesizing that if moth-
ers spoke during pregnancy their female children have a higher incidence of being diagnosed 
with breast cancer. Also, when women smoke before the age of 17 years old or before menarche, 
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they are more likely to be diagnosed with ER positive breast cancer (Jones, Schoemaker, Wright, 
Ashworth, &Swerdlow, 2017, p. 4). This is how critical the effects of health and especially 
smoking is during adolescence.  
 Breast cancer risk increased significantly with number of cigarettes smoked per day for 
all breast cancer (Jones, et. al., 2017, p. 4). Breast cancer risks were raised significantly after 10+ 
years’ duration of smoking (Jones, et. al., 2017, p. 4). Though it is noted that breast cancer risk 
did not increase after the 10-year mark. Breast cancer risks were significantly raised within the 
first 20 years after cessation of smoking and decreased with greater time since cessation (Jones, 
et. al., 2017, p. 4). Breast cancer risk was significantly increased if smoking started at age < 17 
years or between the ages of 17 to 19 years old (Jones, et. al., 2017, p. 4). The risk was signifi-
cantly increased for ER-positive subjects, only for smokers starting at ages < 17 years (Jones, et. 
al., 2017, p. 4), ER-negative subjects were not significant.  
 Relative to age at menarche, breast cancer risks were highest if smoking started at or be-
fore menarche (Jones, et. al., 2017, p. 4). For nulliparous ever smoking women, there was a sta-
tistically significantly increased risk of breast cancer (Jones, et. al., 2017, p. 8). Unfortunately it 
was found a significant but modestly raised risk of invasive breast cancer in ever and former 
smokers, in women who smoked more than five cigarettes per day, had 10+ pack-years of use, or 
had stopped for < 20 years (Jones, et. al., 2017, p. 8). There is also an association between smok-
ing and breast cancer was significantly larger among women with a family history of the disease 
(Jones, et. al., 2017, p. 12). The relative risk of breast cancer associated with smoking was signif-
icantly greater for women with a family history of the disease (Jones, et. al., 2017, p. 12). It is 
concluded that smoking was associated with increased risk of breast cancer, among those who 
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started at adolescent or peri-menarcheal ages (Jones, et. al., 2017, p. 12). It is important to know 
the effects that smoking has on breast tissue because it can affect the outcome later in life. There 
has not been enough research on investigating how women’s awareness of their risk relates to the 
timing of their screening. This qualitative study will aim to fill that gap. 
Barriers 
 The following are barriers that prohibit the trajectory of treatment of effective treatment 
for breast cancer patients: screening age, health insurance, education/women’s awareness, and 
distrust.  
Screening Age 
 As aforementioned, the recommended screening age is 40 years old, unless the subject 
has a family history or other factors, but that can create a barrier because women younger than 
40 are being diagnosed with breast cancer.  
Health Insurance 
 Women without health insurance are less likely to have diagnostic screening mammo-
grams (Shakib, Inungu, & Jahanfar, 2019, p. 1). The importance of health insurance is for ensur-
ing positive healthy behaviors such as screening such as mammograms, and other diagnostic 
tools (Shakib, et. al., 2019, p. 1). Women who reported of having no health insurance coverage 
were less likely to have reported a recent mammogram test compared to women who had private 
health insurance (Shakib, S. H., et. al., 2019, p. 4). Research shows that screening education 
needs to be focused on the population of women who do not have insurance because they are less 
likely to have a diagnostic screening mammogram; due to their insurance status. “Although stan-
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dard practice guidelines for breast cancer are clear, the interplay between insurance and practice 
patterns for the US is poorly defined” (Churilla, Egleston, Bleicher, Dong, Meyer, & Anderson, 
2016). This population is typically unaware of the resources available to cover their mammo-
gram screening regardless of the state of their insurance. “Compared with adequately insured 
adults, underinsured and never insured women were 6% and 41% less likely to receive breast 
cancer screening, respectively” (Zhao, Okoro, Li, & Town, 2018). The group that is particularly 
affected are those who typically do not have their high school diploma. “Effects are larger for 
women with less than a high school degree in states that ban deductibles, a policy like a provi-
sion of federal health reform that eliminates cost-sharing for preventive care. Finally, we find a 
substantial proportion of the increased screenings were attributable to mandates that are not con-
sistent with 2014 recommendations of the American Cancer Society” (Bitler & Carpenter, 2016). 
Increased screenings are occurring despite the recommendations because women are being diag-
nosed with breast cancer younger than the recommended age. The recommended bodies and in-
surance companies need to be educated regarding what is happening with young women. Educa-
tion and awareness are pivotal in the detection and survival of women diagnosed with breast 
cancer. 
Education/Women’s Awareness 
 There must be some accountability. The medical providers can only do so much. That is 
where the patient-provider relationship, or attachment is vital. While it is the medical providers 
responsibility to educate the patient regarding the disease and the process of the treatments, the 
patient also needs to investigate the given literature to educate herself about her type of breast 
cancer, stage, treatments, prognosis, etc. Younger women require more information on what 
  !24
breast cancer is and options of treatment regardless of their preference for participation in the 
decision-making process (Rocio-Saucedo, Gilbert, Gerty, Cutress, Eccles, & Foster, 2018, p. 
166). This way the young woman is educated regarding her options, and she can make the best 
decision for herself and her family. This is similar to that of the attachment theory. The level of 
detail in some categories of information was influenced by individual life circumstances, includ-
ing if women were single or in a relationship, had or planned to have children, or had started a 
professional career (Recio-Saucedo, et. al., 2018, p. 168). Overall, women strongly felt the need 
to be informed before making decisions when choices were available (Recio-Saucedo, et. al., 
2018, p. 170). In order for breast cancer patients to be more aware, at diagnosis, clinicians should 
be required to provide patients with a supportive atmosphere in which women feel more prepared 
to voice their concerns, values, and preferences regarding the treatment path chosen (Recio-
Saucedo, et. al., 2018, p. 173). This highlights the patient-provider relationship. In addition, the 
results urge researchers and public health officials to promote health education at secondary edu-
cational institutions such as high school because it can increase women's understanding of health 
messages which may result in positive health behavior (Shakib, et. al., 2019, p. 1).  
Distrust 
 In the African American culture, privacy and a form of secrecy is not uncommon. It is not 
rare for family members to not know who is battling cancer, and if they do know, they do not 
know the type. Also, in the African American culture, which I can only speak to because I am 
African American, there is a sense of mistrust and disloyalty to the medical community because 
of past medical atrocities such as the Tuskegee Experiment.  
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 Briefly, the Tuskegee Experiment was conducted in the 1940s (and lasted for 40 years) on 
African American men who had the disease of syphilis. The men were from a very poor town in 
Macon County, Georgia, and were told that they were going to be helped for their “bad blood”. 
The medial providers, which was also funded by the United States government, were watching 
the latent affects that syphilis had on their bodies. Unfortunately, it was already known that peni-
cillin helped with the disease, though it was incurable. Though the experiment happened over 70 
years ago, it has been taught to the African American community to not trust the medical com-
munity because of the fear that has been instilled. This fear now in some ways affects women, 
and specifically African American women because they saw and were told about what happened 
to their men and are fearful what could happen to them. A similar act happened to a poor African 
American woman by the name of Henrietta Lacks. 
 Henrietta Lacks is another example of why women from low socioeconomic groups are 
not being seen in the hospital or clinic setting. Mrs. Lacks was a poor, African American woman 
from Baltimore, Maryland. She was diagnosed with cervical cancer, and had her cells removed 
from her, which was taken for science and discovery; unbeknownst to her. Later her cells were 
used for the vaccine of polio, and other medicines and therapies, such as some chemotherapy 
agents. The disease killed Mrs. Lacks, but her cells enabled the livelihood of millions of people 
around the world. The distrust stems from her not knowing her cells were used, and dying poor; 
especially while scientists, and pharmaceutical companies benefited financially from her DNA. 
Now, in 2020, something like that would be unethical. Back then, and without informed consent, 
that behavior was justified.  
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 The lack of trust therefore happens because some African American women feel like if 
they help the medical community concerning their health (breast health) they will not be helped. 
Many African Americans, male or female, do not trust the medical community because they are 
fearful of the mismanagement of their DNA. Racism has a lot to do with medical mistrust. “Our 
research also elucidated that decision-making needs to happen in the context of a trusting clinical 
relationship for patients to label the process as “shared””(Hagiwara, Lafata, Mezuk, Vrana, Fet-
ters, 2019, p.1740). The patient-provider interaction can be positive if from its’ infancy it is trust-
ing and cooperative. The issue regarding the Tuskegee Experiment and the story regarding Hen-
rietta Lacks is that African Americans did not have a positive interaction with their medical 
providers. To combat that, necessary factors such as informed consent and joint decision-making, 
were implemented during consultations so patients felt autonomous over their care and lives. 
 Screening/Policy Recommendations 
 Early detection starts with the patient. It is important the patient know her body, breast 
health, family history, and understand the patient-practitioner relationship. There are many rules 
and standards regarding when women should get their mammography. I will give a multitude of 
opinions, attitudes, and recommendations regarding the mammography screening recommenda-
tions according to The American Cancer Society (ACS), The National Comprehensive Cancer 
Network (NCCN), and The U.S. Preventive Services Task Force (USPSTF). 
Table 1  
U.S. Preventive Services Task Force (USPSTF)  
Recommendation Women at Average Risk 
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(Source: Susan G. Komen, 2020) 
 The U.S. Preventive Services Task Force (USPSTF) recommends women at average risk 
to have mammograms performed, with informed consent from their medical provider between 
the ages of 40-49 (Susan G. Komen). Every two years, they state women should have mammo-
grams from the ages of 50-74. USPSTF does not recommend for or against clinical breast exams, 
as they find there is not enough evidence for either argument. USPSTF found there was no dif-
ference in risk of women dying from breast cancer from the ages of 39-49 who had mammo-
grams regularly, and if there was a difference, they found the difference to be very small (Susan 
G. Komen, 2020).  
 Women should have 3D mammograms annually regardless of their average risk status. If 
women had 3D mammograms every two years, then there is a potential to miss a potential car-
cinogen (cancer) growing; especially if the women are classified to have dense breasts. Addition-
ally, mammograms are the tool to save the lives of women, so the claim that women between the 
Age Frequency Clinical Breast 
Exam
Screening Tool
40-49 Annual N/A Mammogram
50-74 Every 2 years N/A Mammogram
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ages of 39-49 are not distinct in dying, is false. 3D mammograms are the tool to detect the prob-
lem, so no matter the age, there is a difference in risk compared to women who do not have 
mammograms performed. Another saving tool is self-breast exam. When women are in tune with 
their bodies, and understand the difference in how their breast feels, and looks makes a differ-
ence in survival. If a woman sees any differences, then she will seek help (depending of circum-
stances) and have a mammogram or ultrasound to either confirm or deny the suspicion. The Na-
tional Comprehensive Cancer Network (NCCN) has different guidelines compared to USPSTF.  
 The National Comprehensive Cancer Network (NCCN) recommends that women with an 
average risk of breast cancer, start mammography’s at the age of 40 (Susan G. Komen, 2020). 
NCCN recommends every 1-3 years women having clinical breast exams starting from age 25 to 
39; and every year starting at age 40 (Susan G. Komen, 2020). There is a noted discrepancy be-
tween the recommendation of clinical breast exams between USPSTF and NCCN. While the 
USPSTF ultimately sees no benefit in clinical breast exams, NCCN recommends it.  
 Clinical breast exams should be performed, but perhaps it would be best if they are per-
formed annually with a family doctor or a gynecologist. When clinical breast exams are per-
formed annually, the patient and the practitioner are able to have a baseline of what the woman’s 
breast looked and felt like and compare it to proceeding years. Additionally, as aforementioned, 
women should perform breast self-exams monthly, after their cycle, to understand how their 
breasts look and feel, too. The NCCN has more detailed recommendations for women who have 
a higher risk of developing breast cancer based on their genetic predispositions. Screening guide-
lines relates to early detection of lack thereof. There are specific guidelines; however, women are 
still dying and there has not been any research discussing knowledge prior to the screening, how 
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do women and what factors lead them to getting screened earlier? Younger women are dying ear-
lier before these recommendations, no one has examined, qualitatively, women’s early experi-
ences from when they first noticed the problem to when they get screened and diagnosed.  
Table 2 
The National Comprehensive Cancer Network (NCCN) 
Recommendation Women at Average Risk 
(Source: Susan G. Komen, 2020) 
 The National Comprehensive Cancer Network (NCCN) (SEE APPENDIX E) 
Recommendation Women at Higher than Average Risk  
  
 The American Cancer Society (ACS) recommendations for women at higher risk of 
breast cancer is different from the NCCN recommendations. ACS recommends women at aver-
age risk to start the informed decision-making with their health care provider at the ages of 40-44 
(Susan G. Komen). Every year starting at age 45-54, ACS recommends having a screening 
mammogram performed. Every two years (or every year if a woman chooses to do so) starting at 
Age Frequency Clinical Breast 
Exam
Screening Tool 
40 Annual Annual Mammogram
25 to 39 N/A 1-3 Years N/A
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age 55, ACS recommends a mammography, if the woman is in good health. ACS does not rec-
ommend clinical breast exams. 
Table 3 
The American Cancer Society (ACS) 
Recommendation Women at Average Risk 
(Source: Susan G. Komen, 2020) 
The American Cancer Society (ACS) (SEE APPENDIX F) 
Recommendation Women at Higher than Average Risk 
 The consensus regarding the recommendations from ACS, NCCN and USPSTF are that 
women are recommended to have screening performed if they have a family history of cancer, 
have certain genetic makeup and may have had previous radiation exposure. The issue is that 
many women may not know their family history or understand their genetic makeup. In order to 
understand their genes, genetic testing and counseling could be set up, which insurance could 
possibly pay for if the woman had family history and it was justified by the practitioner. Where 
Age Frequency Clinical Breast 
Exam
Screening Tool 
45-54 Annual N/A Mammogram
55 Every 2 years, or if 




an injustice may lie is many women may not know they have a family history of cancer or may 
not have a family history but that does not exempt from being diagnosed from breast cancer. 
These three organizations have different recommendations for when screening should occur and 
what type of screening should be conducted. Regardless few studies have looked at the time be-
tween awareness of the problem and actual screening. There is no research regarding women’s 
early experiences and what potential barriers were in place in getting them screened early 
enough. 
 According to DeSantis, Gaudet, Newman, Miller, Sauer (2019) “Breast cancer is the most 
common cancer diagnosed among US women and is the second leading cause of cancer death 
among women after lung cancer” (p.438). In 2019, DeSantis, et. al. (2019) states that approxi-
mately “268,600 new cases of invasive breast cancer and 48,100 cases of DCIS will be diag-
nosed among US women, and 41,760 women will die from this disease. Eighty-two percent of 
breast cancers are diagnosed among women aged ≥50 years, and 90% of breast cancer deaths 
occur in this age group” (p. 440). There is not just one type of breast cancer, in fact, there are 
multiple types and are varied in stage.  
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Chapter Three: Research and Design Methods 
 The purpose of this study was to investigate potential barriers and gaps in the experiences 
of young breast cancer patients. This was done by using a semi-structured, qualitative interview 
design to explore their medical provider experience and to determine if there were any delays in 
their treatment trajectory by using the methods of phenomenology and social constructionism. 
Research Questions 
For this qualitative study, I have sought to answer the following questions:  
• What are women’s early experiences with their medical providers who have been di-
agnosed with breast cancer? 
• Are there components of women’s early experiences functioning as barriers to get-
ting treatment? 
Study Methods 
 I conducted a series of twenty-one qualitative interviews and used ethnographic coding to 
analyze the data. Ethnographic coding is used to discover knowledge by organizing their behav-
iors and interpreting their experiences. Since the research questions are designed to discover new 
information arising from the interactions between the subjects’ subjective experiences and their 
dynamic environments, the research methods used for this study were guided by theories of phe-
nomenology. Phenomenology is a theory of experience. “Answers to such questions constitute 
the underpinnings of our field. To answer such questions, we can use phenomenology to learn 
from the experiences of others. Some of the questions might be: What is the experience of shame 
and the impact of that experience for medical learners? What does it mean to be an empathetic 
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clinician? What is the medical learner’s experience of failure on high stakes exams? How do ex-
perienced clinicians learn to communicate their clinical reasoning in professional practice? These 
questions that phenomenology can answer, and the insights this kind of research can provide, are 
of foundational importance to Health Professions Education (HPE) (Neubauer, Witkop, & Var-
pio, 2019, p.91). The impact of shame is that medical providers are still stuck in the thought that 
women can be “too young for cancer”, and that women are not insured for certain screening or 
diagnostic testing. To be an empathetic medical provider, the patient-provider relationship needs 
to develop and be strengthened; from that a bond is formed, and empathy ensues. At times be-
cause medical providers may not listen to their patient, or may mistake a malignant tumor for a 
benign mass, there is fear when going into the Doctor’s office. This is how clinical reasoning 
transitions into professional practice because not every patient is the same; therefore, not every 
breast cancer necessarily looks the same.  
 Phenomenological research can broaden our understanding of the complex phenomena 
involved in learning, behavior, and communication that are germane to our field. Incorporating 
phenomenological research methodologies into health professions education (HPE) scholarship 
creates opportunities to learn from the experiences of others.” (Neubauer, Witkop, & Varpio, 
2019, p.95). From a healthcare perspective, I was able to learn the experiences of the breast can-
cer survivors and gather information regarding shared behaviors and experiences that were 
shared. I specifically used hermeneutic phenomenology for this qualitative dissertation. 
Hermeneutic phenomenology “seeks to understand the deeper layers of human experience that 
lay obscured beneath surface awareness and  how the individual’s lifeworld, or the world as she 
pre-reflectively experiences it, influences this experience” (Neubauer, Witkop & Varpio, 2019, p. 
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94). Listening to the breast cancer survivor of the interviews allowed me to gain insight into their 
lived experiences. It gave me a moment of clarity through the eyes of the breast cancer survivors. 
I made assumptions about the breast cancer survivors’ experiences and how they perceived 
boundaries and interplays.  
 Consequently, breaking into their reality was the goal. I was able to view the breast can-
cer survivor’s social world and make sense of it. From that point, I was then able to make an ob-
jective and valuable point of the problem and raise potential solutions.  Qualitative interviews 
were the option of choice because as the interviewer, I was able to gain their trust easily, and they 
were able to share their personal experiences with me one-on-one; which could have not hap-
pened during a focus group. “In many structured interviews the questions are restricted or the 
process is more free-flowing and indeterminate. As with focus groups, an interviews may possess 
a set of questions, but would not see to impose them” (Litosseliti, 2018, p.198). Through the 
qualitative interviews, I was about to gather dynamic, fluid and objective truths from the breast 
cancer survivors.  
 I have chosen to interview these patients to truly understand their experiences in their 
breast cancer journey. Asking the same set of questions enabled me to get a frame of reference of 
how breast cancer patients feel and what they typically go through during their initial presenta-
tion, treatment, and follow-up. The main topics in the interview guide asked the women about 
their early experiences about their breast cancer journey, how old they were at diagnosis, if they 
had children or were on birth control, if they lived a healthy lifestyle, and if they had a family 
history of breast cancer. See Appendix C for the interview guide. Qualitative interviewing sup-
ported the kind of information and probing that was done because I was able to understand their 
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feelings, how they felt toward their doctors, what they understood, and so much more. To some 
degree, I was able to step into their shoes and live in their journey through the interview process. 
In order to understand their early experiences, I had to ask certain questions about their early ex-
periences such as how did their breast cancer present, and what was their journey from clinical 
presentation to their breast cancer treatment? In learning their stories and following their jour-
neys, I was able to conclude potential barriers that may have hindered or impeded their process 
to early treatment.  
Study Procedures 
 Each breast cancer survivor was interviewed [See Appendix C for interview guide] be-
tween 45 minutes to an hour via Zoom application with the video component. The breast cancer 
survivor had the option to not use the video, if she did not feel comfortable. After the interview, 
the file was saved under the survivor’s initials and date of the meeting and transcribed by Otter. 
Otter is a safe artificial intelligence (AI) service that transcribes dialogue.  1
 Ethnographic coding. Ethnographic coding was chosen due to reflexivity. Reflexivity is 
me viewing my own beliefs, and how it may or may not have influenced the research.  The 
women’s breast cancer experiences was observed through a reenactment by interview. Ethno-
graphic coding allowed for a single source to be identified, collected, and triangulated the ideas
—to ultimately develop a grounded theory.  
 Otter is a safe and secure platform in which no other person has access to the interview but me, 1
the researcher. 
 Informed Consent Process. Zoom was the platform that was used, as aforementioned. I 
used Qualtrics to collect and store consent forms. [See the Informed Consent template located in 
Appendix B]. As described above, I contacted the breast cancer survivors via text message and 
then sent them a flyer, via email, with more detailed information. The consent was signed virtual-
ly before the interview.
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Participant Characteristics  
 I enrolled 21 breast cancer women into the research study. All participants were asked 
screening questions to ensure that they met the following criteria. All of the women were over 
the age of 18 years old. The women were younger than 50 years old at the time of diagnosis. The 
breast cancer patients also all were able to speak English and had been diagnosed with breast 
cancer in the United States of America. The women were not hospitalized or on hospice at the 
time of the study or interview. I interviewed 21 breast cancer survivors. One hundred percent of 
them were women. Forty-three percent of the participants were Black, 29% were White, 24% 
Hispanic, and 4% Asian. Thirteen of the breast cancer survivors were diagnosed before the age of 
40 years old. Thirty-three percent of the participants were married before their diagnosis, while 
the remainder were single (not widowed or divorced). Ninety percent of the participants tested 
negative for the BRCA1 and BRCA2 genes. A breast cancer survivor tested positive for the BR-
CA1 gene. Another breast cancer survivor could not remember her result. Sixty-seven percent of 
the participants have dense breasts and that was either known before, or after diagnosis. Ninety 
percent of the participants were employed before their diagnosis with 2 of the participants not 
working (or having insurance). Ninety percent of the breast cancer survivors also had insurance 
prior to their diagnosis. Eighty-six percent of the breast cancer survivors exercised to some ex-
tent, before their diagnosis. Seventy-six percent of the breast cancer survivors drank alcohol so-
cially before their breast cancer diagnosis. Eighty-one percent of the women did not smoke. Thir-
ty-eight percent of the women had a history of breast cancer (or cancer) in their family and 52% 
of the women knew about their family history of lack thereof before their diagnosis.  
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 Two breast cancer survivors had stage one breast cancer. Thirty-three percent of the 
breast cancer survivors were stage II. Nineteen percent were stage III. Nineteen percent were 
stage IV. Other breast cancer survivors could not recall what stage they were diagnosed with. 
Thirty-eight percent of the women were diagnosed with Triple Negative Breast Cancer (TNBC). 
Seventy-six percent of the breast cancer survivors had 1 or more biological children. Ninety per-
cent of the breast cancer survivors were on birth control for either five years or more or a couple 
of days. Fifty-seven percent of the women saw their OB/GYN when they noticed their issue. 
Thirty-three percent of the women saw their primary care provider (PCP). The other 10% were 
referred to a breast surgeon. Ninety percent of the breast cancer survivors had chemotherapy. 
Ninety-five percent of the breast cancer survivors had radiation therapy. One hundred percent of 
the breast cancer survivors had some sort of surgical intervention (biopsy, lumpectomy, mastec-
tomy). 
Data Analysis and Coding 
 After the interviews were conducted, they were converted into a PDF file and uploaded 
into the safe and secure Dedoose database . Dedoose is a qualitative program software. This 2
database allowed me to perform first level and second level ethnography coding. The first level 
coding allowed me to gather the information that would primarily answer the two research ques-
tions, by identifying relationships. The second level coding is more refined, allowing for more 
themes to emerge, confirming ideas. Reaching the second level coding allowed me to find the 
themes. The themes that arose allowed coding to ensue based upon the same questions that were 
asked to the 21 breast cancer survivors. Similar answers were derived from the women, and 
 https://www.dedoose.com2
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themes emerged. The themes will be discussed later in chapter four, but some of the themes that 
emerged were the concept that women are “too young to get breast cancer,” familial responsibili-
ty, prioritizing self, cultural implications, support, self-examinations, patient-provider relation-
ship, religion/spirituality, accurate/adequate screening tools (diagnosis tools), how cancer is 
viewed, education, guidelines and recommendations, earlier diagnosis, privacy, insurance/money 
making, and genetics. 
 Recruitment strategy. As a Radiation Therapist at a local cancer treatment center, I had 
contact with these women being their caregiver; and I developed relationships with the patients 
over the 6 to 7-week treatment period. During informal conversation occurring over treatment 
period patients often initiated request to exchange phone numbers, to remain in contact after 
treatment ended for the purpose of friendship and to simply check in. After 6 to 7 weeks of 
treatment, at times, the term patient changed to friend. This was not an attempt of early recruit-
ment. As a result, I now have a list of breast cancer patients who met the inclusion criteria and 
did not meet any of the exclusion criteria, and who had given me their information with permis-
sion to contact.  
 I contacted the patients of whom I have become friendly with, to ask for their email, and 
sent them a flyer for the interview [See Appendix G for the flyer]. There was compensation for 
participation in this study. If the patients wanted or needed more information, we arranged a time 
to talk over the phone to go over the screening script. 
Threats to Validity  
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 Some of the women were unable to recall the stage they were diagnosed with, their hor-
monal status, genetic status, if they have cancer in their family, and if they have dense breasts. 
Some of the information they were unable to recall or remember was due to the trauma occurred 
in their lives due to a cancer diagnosis. Every breast cancer survivor is within a year to six years 
of their initial diagnosis, for the exception of one participant who is 23 years from her initial di-
agnosis but had three other cancer diagnosis since then. That could present a potential problem 
based on remembrance or recall bias, but one thing a cancer patient can remember is their diag-
nosis.  
Summary  
 The purpose of this qualitative interview was to explore breast cancer patients and their 
medical provider experiences, to determine if there were any delays in their treatment trajectory 
by using the methods of phenomenology. In addition, the purpose of this study was to investigate 
potential barriers in their experiences as patients.  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Chapter Four: Findings and Recommendations 
Introduction 
 The purpose of this qualitative dissertation is to determine, the gaps and barriers, if any, 
to breast cancer patient’s treatment; and if their medical providers played a role in that process. 
In this chapter, I will cover the breast cancer survivors background and qualifications for the ba-
sis of the interview, and themes. The research questions are: What are women’s early experiences 
with their medical providers who have been diagnosed with breast cancer; and are there compo-
nents of women’s early experiences functioning as barriers to getting treatment?  
Patient Background Information 
 Each of the 21 breast cancer patients shared three commonalities: they are women, have 
breast cancer, and were diagnosed at an age less than 50 years old, all within the United States. 
The participants have various backgrounds ranging from genes, menstrual status, marital status, 
children, careers, education, race, religion, family cancer history, being premenopausal, maternal 
smoking and age. Each of these women were brave enough to share their story in the hopes that 
they can inspire patients, medical providers and in my hopes, policy change.  
 I have interviewed women who are Black, Hispanic, White and Asian. The age of which 
they were diagnosed with breast cancer ranges from 28 to 40 years old. Many of the women in-
terviewed are within 5 years post their diagnosed age. Many of the women have been on birth 
control from 5 years to longer, with someone being on birth control for days, and others not be-
ing on birth control at all. All the women have and birth children, except for four women who 
have not had children at all (birthed, surrogacy or adopted). Many women knew of their breast 
cancer stages, while few of them did not remember. There stages ranged from Stage I to Stage 
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IV. Including knowing their stages, many women could remember their hormonal status, while 
some could not. Some women were ER- PR- HER2- (Triple Negative) and others were estrogen, 
progesterone and HER2+ (ER+ PR+ HER2+), with a range of other variables. Many of the 
women were negative in carrying the BRCA1 or BRCA2 genes, while one woman was positive 
in being a BRCA1 carrier. All the women were either married or single at the time before their 
diagnosis —none of them were divorced, or widowed.  
 The women either knew their family history, did not know, or found or after their diagno-
sis. For the most part, the women did not smoke, they did drink socially, and ate relatively 
healthy, as well as, exercised. It is interesting to note that the mothers gave birth at young ages, 
ranging from 19 to 35 years of age. All the women had insurance prior to their diagnosis, except 
for two. Additionally, all the women worked during treatments, except for  two women. The type 
of medical provider that they women reached out to or was referred to, OB/GYN, PCP or a 
Breast Surgeon. Many of the women either knew, and later realized they had dense breasts, ex-
cept for one, and four other women who were not certain. All the women have had some sort of 
surgery, the majority had chemotherapy as well as radiation therapy.  
Themes 
 General themes that arose were the concept that women are “too young to get breast can-
cer,” familial responsibility, prioritizing self, cultural implications, support, self-examinations, 
patient-provider relationship, religion/spirituality, accurate/adequate screening tools (diagnosis 
tools), how cancer is viewed, education, guidelines and recommendations, earlier diagnosis, pri-
vacy, insurance/money making, and genetics. The first section below describes the themes relat-
ing the women’s early experiences with their medical providers, and the second section describes 
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the themes that relate to components of women’s early experiences functioning as barriers to get-
ting treatment.  
 I have incorporated the voices of the twenty-one women who wanted to share their sto-
ries. You will meet JR, MC, CP, LM, TM, SFR, MW, CW, CR, AD, JamRiv, TD, LynMit, KS, 
JK, SMC, DD, DSM, BMD, YMD, and MV. Their stories embody all of the themes that 
emerged. Their stories are the reason why literature, policy, recommendation, and guidelines, 
cannot always be followed; and the rules must be broken to save the lives of the women who 
were also diagnosed with breast cancer.  
Women’s Early Experiences 
Too Young for Cancer 
 A lot of the women expressed that their providers kept telling them they are too young for 
cancer. Many of the women advocated for themselves to get screened despite their age. Now 
some of those women, young women, have stage IV breast cancer. The breast cancer spread from 
their breast to their bones, lung, and brain. They were originally told they were “too young” for 
cancer, and they could wait a couple to see what happens. Now, they only have a couple months 
for the rest of their lives.  
 Meet MC. MC is a young married woman, with one beautiful daughter, who felt her 
mass, and decided to seek help. MC  stated, “I was young, it was so tiny, and I have no family 3
history. They [the medical providers] said they weren’t concerned”. She was diagnosed with 
stage II breast cancer at the age of 34. Similarly, another young woman, single woman was diag-
nosed with breast cancer at a young age.  
 Using Initials to protect breast cancer survivor confidentiality. 3
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 Meet CP. CP is a young, African American woman. CP stated, “He was like you’re 
young. So, it’s probably not cancer”. She was diagnosed with Triple Negative Breast Cancer 
(TNBC) at the age of 28 years old. “I think it is common, especially in a lot of young survivors 
hearing, you're too young for cancer, you know. I think depending on the person, they might take 
that further than I would and say, Well, I'm too young. So, I'm not going to prioritize this.”  CP 
emphasized that she was one of the young women that pushed for more diagnostic testing, re-
gardless of her age. She is happy that she did because it saved her life. CR is another young 
woman who fought for further diagnostic testing despite her young age.  
 CR is a young Caucasian woman. She has been engaged for years to her long time 
boyfriend. She discovered her lump herself, and sought help. CR wants to let everyone know 
that, “You're never too young for cancer. I'm 29 years old, and I was diagnosed with cancer, you 
need to check yourself. Don't wait until you go for GYN appointment; You’re never too young 
for cancer. You see children get cancer all the time.” CR mentioned that she does not understand 
how medial providers can mention that women are too young for breast cancer when children are 
diagnosed with cancer all the time. She states the notion of “too young” for breast cancer needs 
to be null and void, regardless of age.  
 Meet LynMit. LynMit has two amazing sons, and was diagnosed with Triple Negative 
Breast Cancer (TNBC) at the age of 41. She stated, “I actually begged and pleaded to get mam-
mograms at like, I don't know, like, 35 or something I had started because I knew about my mom 
[who was diagnosed with breast cancer]. You know, they said that I was too young. And don't 
worry about it unless I feel something.” Although since her diagnosis she has had a wonderful 
experience, this unfortunately highlights the notion of once again, women being “too young” for 
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cancer. Literature and research will stand on that if her genetic testing was negative, there would 
be no need for her to have further screenings performed because of her mom’s breast cancer di-
agnosis. I would have to insert my opinion from what I have seen, and from the interviews con-
ducted, it is possible, that had she had been screened years prior; her diagnosis might have been 
less severe. Another young woman, DSM, had a similar story to tell.  
 DSM had a similar experience, stating, “I tried to call the doctor. And I was like, Hey, 
listen, there's a lump. And the doctor was like, No, you're only 28.” She was also diagnosed with 
TNBC at the age of 28 years old. Meet DSM. DSM at the time was a young African American 
woman, who later married, and had two beautiful children (a girl and a boy). DSM story is quite 
different, she had fought through three cancer diagnosis all stemming from her original breast 
cancer diagnosis from her early twenties. She wants every woman to know, listen to her body, 
push, and be her own advocate. Similarly, JanRiv is another young woman who had to be her 
own advocate.  
 Meet JR. JR is a young Caribbean woman who birthed two beautiful children, a girl and a 
boy. JR was told, “When I got there, they kind of gave me a little bit of pushback, saying Oh, 
you're so young. Why do you need this? And I'm like, Well, I have a referral. Yeah, my breast 
hurts. And I will pull it out if you need me to. But they eventually saw me. And once they saw 
me, they were like, nope, you can't leave we have to do some other tests.” She was later told she 
had TNBC at the age of 29 years old. Not even two years later, she was told she had a tumor in 
her lung, which was able to be removed. Months later, she was told she had a tumor in her brain, 
which was also able to be removed. I guess she is not too young for breast cancer.  
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 Women are not “too young for cancer.” As themes emerged, women can be as young as 
28 years old who are diagnosed with breast cancer. Literature states that mammograms should be 
performed at a baseline, annually, starting at the age of 40 years old—I believe these women in 
their twenties beg to differ. These findings are not consistent with the literature that I presented in 
Chapter Two, especially related to the age of patients. As discussed in Chapter Two, we learned 
that age can be a risk factor for women being diagnosed with breast cancer (Sisti, Huayllani, 
Boczar, et al., 2020). Meaning women who are diagnosed under than age of 40 years old have a 
higher stage of breast cancer, therefore, in many cases, decreasing their prognosis. We also 
learned a study in Norway took place endorsing that young women are indeed being diagnosed 
with breast cancer, therefore, the mammogram age should be lowered (Albrektsen, Heuch Tretli 
& Kvåle,1994). The women that I have interviewed not only are some younger than 40 years old, 
and are diagnosed with breast cancer, they are being diagnosed with aggressive types breast can-
cer.  
 Their cancer is metastasizing (spreading) to their bones, lungs and brains; and many of 
them did not have a family history. This notion of women are “too young” for breast cancer 
needs to cease. It is most certainly unfortunate because women those ages should not have to 
deal with a breast cancer diagnosis, but the reality is, they are. The baseline of annual mammo-
grams, starting at the age of 40 years old should be modified to a younger age to incorporate the 
younger women who are being diagnosed. It is interesting because many of the women felt their 
lumps during their breast self-examinations, although most literature, as presented in Chapter 
Two, does not necessarily endorse self-examinations. As previously stated, USPSTF does not 
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recommend for or against clinical breast exams, as they find there is not enough evidence for ei-
ther argument (Susan G. Komen, 2020).  
Self-Examinations 
 Self-Examinations are extremely important. This gives the woman a baseline of what her 
breast looks and feels like. From that initial presentation, she is able to see any potential changes 
that occur. Many of the women self-examined themselves, and self-palpated their own masses. 
This is important because as stated in Chapter Two, this goes against literature. Current guide-
lines, according to the ACS, and USPSTF, do not recommend or endorse palpation as there is not 
seen an increase of mortality from palpation to screening. Although, the women who felt their 
masses, would beg to differ.  
 Meet SFR. SFR is a woman who was diagnosed with breast cancer at a young age. She is 
a wife and a mother of two wonderful children. SFR said, “So I had actually had my mammo-
gram, like in February. And I just decided in April, can we do a self-examination and I found this 
lump like right above my breast on the on my on my left side.” SFR was diagnosed with stage 
IIB, ER+ PR- HER2+ breast cancer. CR also mentions self-examination as part of her journey. 
 CR expresses, “So you definitely need to do self-breast exams, no matter if it's, you 
know, how they want you to. I found mine in the shower. I lifted up my arm and was just feeling 
around because you know, you're soaping up yourself.” DSM also endorse self-breast examina-
tions.  
 DSM states, “It is so important for women to know and learn to be comfortable with their 
body so that they can know what is good and what isn’t good.” This is how a lot of the woman 
found their masses, from feeling their breasts, and knowing their bodies.  
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 There is a controversy regarding if and when women should perform self-breast examina-
tions. The multitude of women that felt their lumps when feeling their breasts, in the shower or 
while laying on the bed, or because their medical provider felt their lump, would agree with the 
concept that breast examinations are lifesaving. These findings are not consistent with the litera-
ture that I presented in Chapter Two. The U.S. Preventive Services Task Force (USPSTF) does 
not endorse or recommend for or against clinical breast exams, as they find there is not enough 
evidence for either argument, as aforementioned. Similarly, The American Cancer Society (ACS) 
does not recommend clinical breast exams. Additionally, The National Comprehensive Cancer 
Network (NCCN) would recommend women between the ages of 25 to 39 to have a breast exam 
1 to 3 years, and starting at 40 years old, annually. The women I interviewed would agree the 
breast exam saved their lives, and the breast exams should occur regularly and often.  
 The literature suggests that self-examinations has no survival rate, compared to women 
who have annual mammograms (Susan G. Komen, 2020). There is not seen to have a significant 
mortality rate between the two. The issue is there is an obvious mortality rate increase because 
the women who are “too young” to have a screening mammogram due to their ages would have 
to wait until they reached the age of 40 to have the screening, unless self-palpation occurred—
therefore, decreasing mortality, presumably. This is why it is very important to have a relation-
ship with the medical provider and the patient. The patient-provider relationship is paramount. 
This relationship allows the patient to trust the doctor with the needs that she has, and allows the 
provider to follow through.  
Patient-Provider Relationship  
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 A myriad of women stated the importance and effectiveness of the patient-provider rela-
tionship and expressed their feelings on the matter. 
 MC expressed, “At that time, I thought, well, she's not concerned. She's right. I am 
young. I'm looking back. I'm like, thank goodness that the type of breast cancer that I had wasn’t 
worse, you know, thank God, it wasn't, triple negative or, you know, worse or more aggressive”. 
MC had to advocate for herself despite her provider not believing she could have breast cancer. 
She was diagnosed with stage II breast cancer at the age of 34 years old, as previously men-
tioned.  
 Meet LM. LM is a beautiful successful, Caucasian woman. LM states, “I wish that the 
doctor maybe did things a little bit differently. Fortunate for me, I, did advocate for myself to 
make sure I got the mammogram and everything, but I feel like there's probably a lot of women 
that would have just taken her word for it and moved on.” LM was 35 years old when she 
learned she had ER+ PR+ HER2+ breast cancer. LM had hoped that the relationship had been a 
little bit stronger. Sometimes you wish you do not have to advocate for yourself that much or that 
hard, or that often. On the other hand, MW had a positive experience with her provider.  
 Meet MW. MW was diagnosed with the BRCA1 gene prior to her breast cancer diagno-
sis. As she would explain, although the provider explain that one day she could possibly be diag-
nosed with breast cancer, the provider also made it seem like because she was young, she was far 
off from that fact. MW is a young woman with a son, and has a loving husband. MW expressed, 
“In the beginning (after her diagnosis), everybody was amazing. And I will say that every doctor 
here was caring because they challenged me. I've never felt just like a number. I felt like we were 
actually involved in my case.” This relationship is important. Especially Never feeling like a 
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number. Although physicians are extremely busy, patients should feel just as important, and 
cared about as the next. Also, in feeling comfortable in the care of the medical provider, that in-
cludes, talking in a common language.  
 CW expressed, “Like, what is his language?” In addressing medical providers using med-
ical terminology, instead of Laymen’s term. And additionally, she wanted to know, “What ques-
tions should I ask?” She wanted to be educated about the cancer process. Also, she states, “But 
there's no consideration for the person who has never entered that space. I'm a layman. I don't 
know your terminology. I don't know your inferences.” Meet CW. CW is a single mother who 
has a two children. She followed the mammogram guidelines perfectly. She was told because her 
previous mammogram was clear, she could wait two years for another one. She wished that was 
not a sound guidelines. She was diagnosed with breast cancer. 
 CW also expressed, “But my point is no explanations in there. You know that communi-
cation will allow for a patient to understand what they're walking into. Emotionally, the level of 
anxiety was very much heightened. I was very vulnerable. I had to give all my trust to this person 
that I quite frankly did not know.” This is another reason why the patient-provider relationship is 
so important. During the times in their lives where some of these women are meeting these med-
ical provider for the first time, care needs to be established, as well as, trust, commitment and 
adequate care.  
 CR talks about how her male provider did not seem to be concerned about the lump that 
she found. He had a female provider palpate the area of concern. “You know, he's a man. So of 
course, he had to go get a female to come in. So, I feel like he would have brushed it off if I 
didn't push for it.” She felt like because of his gender, he would not have pushed for more test-
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ing, nor maybe not knew what to look for. She is very thankful that the female provider came in 
and palpated her mass, and sent her for further testing. She also explained the frustration of when 
getting treatments and the lack of communication in regard to screening in between treatments.  
 CR also expressed, “And that's one thing that I can say, that really bugged me and was 
always in the back of my mind the entire time was, Why do they not check you like midway 
through?” “It's just the unknown of, is it working? Or am I just sick for nothing? And some peo-
ple may not even want to know, but they should at least ask.” Patient-provider relationship also 
includes communication. It is important that throughout the woman’s journey she is being com-
municated to, if that is what she wants. CR also remembers a time when there was poor commu-
nication and seemingly insight.  
 CR also states, “I was telling her about symptoms and my tumor and she's looking at the 
ultrasound she’s like, Oh, it’s a cyst. She's like, you wouldn't have this shadow you wouldn't have 
any pain either. Well, guess what? You have pain with a tumor!” CR wants to reiterate that she is 
not sure how other women’s diagnosis presented, but this is how hers presented. She had pain, 
and on her image, there was obviously a shadow, and it was not a cyst. She is not taking anything 
away from the work that medical providers do. CR is simply emphasizing that every woman is 
not textbook. Every woman is different. Some women experience pain prior to their breast can-
cer diagnosis, just like she did. 
 Meet JamRiv. JamRiv is a young married woman. She has two boys and was diagnosed 
with stage IV breast cancer. The cancer was all over her body at the time of diagnosis. She ini-
tially thought she had a cold, then a pinched nerve. An ultrasound was performed, and many 
masses was seen on her liver. JamRiv was diagnosed at the age of 39, shortly after her husband 
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was diagnosed with colon cancer. JamRiv stated, “I had a history of fibrocystic breasts and from 
16 years old and then in 2015 I had a miscarriage where my breast engorged, and the right breast 
didn't necessarily go back to its original state. And I did share that with my OB/GYN at the time. 
And she wasn't too concerned just because that breast was always the one that produced the most 
milk and all of that, so I thought that it was maybe a blocked milk duct or something like that.” 
She had a conversation with her medical provider about her breast history and her gynecological 
history. Also, there are many instances where medical providers advocate for their patients.  
 Meet TD. TD is a beautiful woman, and great mother to two women.  TD was diagnosed 
with TNBC. TD expresses how her medical provider advocated for her. She stated, “He kept say-
ing, you know, something is there, we see something, it's hidden. So, he didn’t give up and ac-
cording to him, he said they had a whole bunch of other doctors from a different state looking at 
my imaging.” This is a beautiful example of a wonderful patient-provider paternal relationship. 
Her medical provider fought for her because he saw something, and she trusted him because of 
his expertise. It is always important that the medical providers always look at the patient, and not 
just the disease.  
 Meet JK. JK was diagnosed with Stage IV, HER2+ breast cancer at the age of 30 years 
old. She was one daughter that she keeps fighting for. JK mentions, “I wish that the doctors took 
a step back and looked at the person and not just at the cancer.” This is very important. To treat 
everyone as if they were part of your family, friends, or special group of people.  
 DSM states, “Doctors need to listen to their patients, not everybody's a flipping 
hypochondriac. Listen to your patient.” She also gives advice stating, “I know that doctors see a 
lot of patients all the time, but this is some serious crap that we're going through. Don't treat us 
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like we're sitting there trying to butt in line at the grocery store with 10 packages in a five-pack-
age lane. Have some compassion. I think that they could learn emotional intelligence.” 
 In Chapter Two we learned that in order for breast cancer patients to be more aware at 
diagnosis, medical providers should be required to provide breast cancer patients with a support-
ive atmosphere in which women feel more prepared to voice their concerns, values, and prefer-
ences regarding the treatment plans and trajectory’s (Recio-Saucedo, et. al., 2018, p. 173). This 
highlights the patient-provider relationship. In addition, the results urge researchers and public 
health officials to promote health education at secondary educational institutions such as high 
school and colleges because it can increase women's understanding of health messages which 
may result in positive health behavior and possibly prevention (Shakib, et. al., 2019, p. 1). 
 Many of the breast cancer patients had a variety of experiences with their medical 
providers in their early experiences. What can be extrapolated, is that the early experiences with 
their medical providers creates the trajectory of treatment success, when they are compliant. The 
patient-provider relationship is extremely important in the initial days of the findings, diagnostic 
scans, and diagnosis; leading up to treatment. These steps are imperative because it creates a 
bond of trust, and reliability in a vulnerable stage in their lives. What also helps these women 
during these vulnerable stages in their lives in connecting to God or a higher power, in their reli-
gion or spirituality.  
Religion/Spirituality in Cancer Diagnosis 
Amid a cancer diagnosis the women still have a positive outlook on their experiences, some 
credited that to religion or spirituality. 
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 MC stated, “I just feel like I’m not in control. That is partly my religion. I'm not in con-
trol; and I think God had a plan for everyone”.  
 SFR expresses, “He [God] was my only option. But it was an option that I desired to 
want to do. And by me doing that, it caused them [her children] to have that same desire.”  
 MW said, “I'm a Christian. Prayer definitely helped.”  
 JamRiv expresses, “I try not to question his path for me. And so, with my diagnosis, it 
was just also unfathomable to me because my husband had already went through a colon cancer 
battle, so it was like, my kids have two parents with cancer and it was just, like, inconceivable to 
me. I am appreciative of the extra time that I have. Because if I hadn't got that ultrasound, I could 
have been much, much worse.” 
 JK has a positive outlook on her journey. She states, “I try to keep my smile. Because 
that's one thing that people have always said, I've never lost my smile. So, I just want to tell peo-
ple, you know, always think of the positives, you know, because there's a lot more people that's 
going through worse situations than what you are.” 
 SMC talks about a spirituality of embracing her diagnosis, “So I embraced the cancer.” 
She was 38 years old when she was diagnosed with breast cancer.  
 Meet BMD. BMD is a Mexican woman who has two children, is married, and was diag-
nosed with breast cancer at the age of 36 years old. She expressed that as a Mexican woman her 
duty is to take care of her family, and her household. She is the last on the priority list, until her 
body made her sit down, and listen to herself. BMD expressed, “I don't believe in God. You 
know, I am. I'm not going to any church right now. Or I wasn't going any church even before. 
Um, but I have my sister, she's a Christian And, and she's been like, you know, sending me some 
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messages and sending me like, some Bible scriptures. And videos about like, the pastor is talking 
about God and all that stuff. And I'm, and I like it, and I think that makes me feel better.” Simi-
larly, MV has an interesting story.  
 MV is a mother and a wife. She is of Hispanic origin and had to wait for diagnostic test-
ing to be performed due to lack of insurance. MV states, “I’m very positive all the time.” MV 
was 43 years old when she found out she had stage IV breast cancer.  
 The interviews revealed that a positive mindset, a healthy attitude, and/or a spiritual con-
nection really help cancer patients get through the trials in their journey. The women who were 
interviewed really pointed to the positive mindset and the manifestation that they garnered in or-
der to get them through the process of their breast cancer treatments. The themes of this magni-
tude were not found in previous literature. 
Diagnostic Tools 
The women also expressed the need for more accurately applied diagnostic tools. 
 Meet TM. TM is a beautiful mother to a wonderful son. She was diagnosed with breast 
cancer at the age of 32 years old. Prior to her diagnosis she was originally told that there was 
nothing there until she advocated for herself and followed up. Not only does she advocate for 
herself, she advocates for better screening techniques and protocols. TM stated, “But they said I 
had dense breast tissue, so it was hard to see on the mammogram. You couldn't see it at all but 
could detect it on the MRI.”  
 TM expresses, “At this point with young women, if we have dense breast tissue, and 
that's a known fact. And we come in with some type of symptom. Why do we stop at a mammo-
gram if nothing is seen on the mammogram? Like if we know that young women, this is a risk to 
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them, then just go straight to the MRI. And I had mentioned that to the radiologist that I met with 
a couple weeks afterwards and she was like, you know, insurance doesn't pay for that immediate-
ly. That’s not the first line of defense. And I'm like, well, it needs to be for young women with 
dense breast tissue because you can't see anything on a mammogram. So, what's the purpose of 
the mammogram?” She was 32 years old when she was diagnosed with IIIB breast cancer, as 
previously mentioned.  Similarly, CR endorses the breast MRI for the first line of defense for 
women, young women, with dense breast tissue.  
 CR states, “You know, when you're younger, you have denser breast tissue, and then it 
[mammogram] doesn’t pick up that [cancer], and then maybe they need to find something that 
does that. Give us an MRI.” ADG feels the same way.  
 Meet ADG. ADG has four children and was diagnosed with Stage II breast cancer, ER, 
PR +. ADG expresses, “I think the one thing I learned here is not just trust the mammogram. And 
if there's like, questionable, then you have you have to have to be your own advocate. Because I 
felt it.” ADG is expressing that she felt her lump, but the mammogram did not pick it up because 
she has dense breasts. She also states, “And the thing also is the mammogram, because my breast 
tissue is dense. They should give us an MRI.” She states it is important to always advocate for 
yourself. She was 45 years old when she was diagnosed with stage II HER2+ breast cancer. 
JamRiv asked for further screening prior to being diagnosed with Stage IV breast cancer because 
of her cancer history on her father’s side.  
 JamRiv expresses, “I can say that, I would ask about any type of screenings or things like 
that, and they didn't think that I had a strong history in order to justify that because the breast 
cancer that is in my family was on my father's side.” Diagnostic tools are still being debated re-
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garding when they should be had, at what age, etc. The women that I interviewed, would all 
agree, more advanced and specified diagnostic tools should be taken for the betterment of the 
patients.  
 As we learned in Chapter Two, the screening tool of choice is the mammogram for 
women of average risk and high risk between the ages of 40 to 74 years old (Susan G. Komen, 
2020). According to Susan G. Komen (2020) the breast MRI is an option for women who previ-
ously had cancer, or have a gene mutation, and that screening process can begin at the age of 25 
years old. Women who have had radiation to their chest between the ages of 10 to 30 years old, 
can have a breast MRI, annually, starting 10 years after their radiation exposure; have dense 
breast tissue, women who have a greater than 20% risk of invasive breast cancer based on their 
family history (See Appendix E and F). The problem is this is the only way, seemingly, a breast 
MRI can be the first line of defense, and there are many women who have dense breast tissue, 
who are not always afforded an MRI.  
 The current screening recommendations state that insurance should cover mammograms 
annually, starting at the age of 40 years old. The issue that presents is that women who are less 
than 40, and some who are 40 and older have dense breasts. Dense breasts, simply put, makes 
breast tissue difficult to see diagnostically on a 2D/3D mammogram, at times. Other diagnostic 
tools such as an ultrasound or a breast MRI can be used to further evaluate breast tissue. This is 
what some of the women were expressing, other diagnostic tools, such as the breast MRI, would 
be useful. These findings are not consistent with the literature that I presented in Chapter Two, 
cited from Susan G. Komen. Breast MRI is not the first line of defense, diagnostically, because it 
is more expense than a 3D mammogram, for example. At times, the cost benefit analysis out-
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weighs performing a mammogram versus a breast MRI. The women interviewed would agree 
their lives, and the lives of other women far exceed the cost benefit of a breast MRI. This type of 
diagnostic tool, and others, help aid in early diagnosis.  
Earlier Diagnosis 
Also, a lot of women wish they the cancer was diagnosed sooner. 
 LM states, “I wish that I had taken the initiative a little bit sooner.”  
 The breast cancer survivors also talk about finances and insurance. 
 TM expressed, “I couldn't financially live off the short-term disability or long-term dis-
ability. I needed my entire income. So thankfully, I had a boss that was supportive”.  
 CR stated, “I wish would have found it sooner. But then again, I'm like, did it [cancer] 
come from the miscarriage, you know, and would I have found it sooner or if it came from the 
miscarriage, then maybe it wasn't there to find sooner. I don't know.” It has been proven that 
younger women can get breast cancer; therefore, early diagnosis would be advantageous in sav-
ing lives, not just for them, but for all women. These findings are not consistent with the litera-
ture that I presented in Chapter Two. As Sisti, Huayllani and Boczar , et al. (2020) stated, 
136,525 patients are diagnosed with breast cancer, and they were less than 40 years old.  
 Other points in the interview that were mentioned was the importance of privacy.  
Privacy 
 Some women prided privacy over their diagnosis. 
 SFR stated, “I don't know, for lack of a better word, grief and pain that I was experienc-
ing some of that tried to keep private. But some things I couldn’t.” Similarly, MW, expressed the 
need for privacy.  
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 MW expressed, “I just need you all to respect my privacy. I’m not an attention person”. 
Some of the women expressed their need for privacy. In the time of their lives where so much is 
out of their control, they wanted to control what they could—and one of the those aspects was 
the need for privacy. Some these themes where not found in literature, but arose in the inter-
views.  
Genetics 
 MW expressed the importance of genetics and how she felt like her provider did not ex-
plain the severity of the genes. As previously mentioned, MW was diagnosed with the BRCA1 
gene prior to her breast cancer diagnosis. As she would explain, although her medical provider 
explained that one day she could possibly be diagnosed with breast cancer because she carried 
the gene, the provider also made it seem like because she was young, she was far off from that 
fact. 
 MW states, “It wasn't explained to me the way they I understand it now, and the severity 
of being a BRCA1 carrier,” “If I would have known like I said the severity of being a BRCA1 
carrier, I would have done something, no question.”  
 MW also stated, “They don't tell you, all you need to know about is BRCA1 and BRCA2. 
But now that I know the difference. BRCA1, your chances are higher, you could get breast can-
cer and ovarian cancer.”  
 MW expresses, “People don't understand. I really wish that more is put out there. There's 
some people that don't even know about genetic factors.”  
 What we learned in Chapter Two is that genes are very important because mutated genes 
can be inherited from the mothers or fathers side. It is important to know this type of information 
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because knowledge is power. For example, MW, was able to have genetic testing down because 
her father and the members of his family had breast cancer. It turned out she had the BRCA 1 
gene. She also was later diagnosed with TNBC, which we also learned from Chapter Two that 
black women have a 47% prevalence rate compared to their counterparts. 
  The importance of genetics was a theme that really stood out in the interviews. Accord-
ing to DeSantis et. al. (2019) genetics is seen as important because it can determine the woman’s 
potential increase risk of developing such cancers, such as breast, ovarian, and endometrial can-
cer. Additionally, such knowledge, women can have the power to give to her family members, as 
well as, determine what she wants to do medically to herself, such as have a double mastectomy, 
hysterectomy, and continued scans. The women discussed the importance of such knowledge and 
having the information from their medical providers and possibly a genetic counselor to make 
informed decisions regarding their health.  
 The women’s early experiences related to being told they were “too young” for cancer, 
although most of them self-palpated their mass. The women went to their medical providers, be-
ing their OB/GYN, primary care physician or surgeon and sought help. From the initial presenta-
tion, their primary care doctor set them up for a diagnostic screening tool, primarily the 3D 
mammogram. Some of the women were diagnosed early, some were later in their breast cancer 
stage. The survivors mentioned that in their cancer diagnosis they prided and wanted privacy and 
wish they understood the greater concept of genetics, and the role that it plays. Their early expe-
riences shaped their trajectory into treatment. Some of the women were able to see their medical 
provider, was sent for a scan, and was diagnosed, and proceeded with treatment. Other women 
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had to wait because they were either told due to their age, they could wait for a variety of rea-
sons, or other women needed to take care of their families first, or wait until they had insurance.  
Potential Barriers 
Financial Responsibility  
 Women have the financial responsibility of taking care of themselves and of their fami-
lies; unfortunately, a potential barrier stems from having to financially take care of their families 
before a diagnosis therefore delaying their trajectory of treatment. Working provides financial 
stability needed, and sometimes women cannot afford to not work.  
Familial Responsibility 
 Culturally, women are responsible for taking care of their families first, and then taking 
care of themselves second. This is a potential barrier because in place themselves last, they are 
not taking care of themselves therefore hindering their success of treatment and prognosis. 
Many women placed the responsibility of having a family and raising their family in front of 
their personal needs and health. The breast cancer survivors also had to consider making family 
decisions when being diagnosed.  
 CW said, “Now I'm dealing with my family because I have to make family decisions. Do 
I tell them? Do I not tell them? I have children!” Not only dealing with the cancer diagnosis, CW 
must make decisions whether to tell her family. JamRiv recalls being held accountable for her 
family as well. 
 JamRiv recalls her situation, “I saw how long when my husband had his cancer battle, 
how long it took him to qualify, well actually had a liver transplant and it took him like a year to 
be approved for disability. And I felt like with everyone being on my health benefits, and. I'm the 
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primary breadwinner then I couldn't afford to just roll the dice and see if I would be able to have 
health insurance coverage and money for bills and stuff like that. So, I figured I had to  
keep working.” The role of a provider is prioritizing the family regardless of the situation, and 
that is exactly what JamRiv had to figure out. She was 39 years old when she was diagnosed 
with stage IV metastatic breast cancer, as previously mentioned. The role of a mother, and care-
giver is what BMD also knows all to well. 
 BMD states, “I didn't pay too much attention. Because I have my two kids and my son, 
he's now autistic. I was just too busy with my son and taking care of his behavior. You know, I 
didn't realize that I need that time for myself too.” She also stated, “Both of my grandma's die 
before my grandpa's. Oh, you know, and I believe that's because they take care of the husband 
and the kids, but they don't take care of themselves. And I ended up doing the same thing, be-
cause I was taking care of my son, and trying to make, make him feel better. And do better in the 
school. And I wasn't taking care of me, and, and now I'm glad that I can still take care of my son 
because I'm alive.” The role of a mother is very strong and pronounced, and oftentimes, she is 
not the primary concern. BMD had to learn the hard way what it means to not prioritize self. 
Prioritizing Self 
 What many of the women realized is that they did not prioritize themselves before their 
breast cancer diagnosis. They were prioritizing their families, work, and dealing with the stres-
sors of everyday life. After their diagnosis, the women noted to put themselves first, and take 
care of themselves. Literature has shown that although women typically chose their families over 
themselves, which has turned out to be true; during diagnosis the women learn putting them-
selves first was also priority.  
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 MW expressed, “I can't worry about anyone else.” She was diagnosed with TNBC at the 
age of 37, after testing positive for carrying the BRCA1 gene.  
 CW who was diagnosed with breast cancer at the age of 48, after being told 2 years prior 
she did not need a mammogram because her previous mammograms had been clear said, “Still 
trying to take care of myself.” The theme of self-prioritization is paramount.  
 KS stated, “The most thing that I reflected on during all of this was that I need to priori-
tize my health. My physical health or mental health as well. Understanding that it is important to 
put yourself first.” KS was diagnosed with breast cancer at the age of 47. KS is a mother of two 
beautiful children, a daughter and a son. She is Hispanic, a very proud Peruvian. While she 
would do anything and everything for her children, she also understand the importance of taking 
care of herself. She understands the saying, “You can’t pure from an empty cup”. This is part of 
cultural implications.  
Cultural Implications 
There are many cultural implications regarding why certain cultures do not get mammogram 
screening or enroll in clinical trials, or even deal with medical professional because of status, 
stigma, and pride. Some cultural implications suggest  the Tuskegee Experiment, but never 
touched on other cultural implications such as the Hispanic or Latino experience.  
 TD states, “And it's something that I noticed the background or the history with African 
Americans or not, but, it kind of seems like to me that, um, it is kind of taboo, when you start 
expressing how you really feel. Or for people to really just be there for you.” In addition, TD 
states, “And that's why I throw the race card out there like that, because that's how I felt like as 
African Americans, especially women, you know, you should be there helping me through this, 
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but instead, because you know, I'm a strong individual. You're letting me go through this alone, 
basically, because you know, I got it.” Being African American TD noticed in her experience that 
there is a stigma for Black women to ask for help in their time of need. TD was diagnosed at 46 
years old with TNBC, as previously mentioned.  
 KS talks about cultural implications in the Hispanic community. “When I was there, like 
obviously, there was like support groups and like psychologists that you can talk to and stuff, but 
I guess my main concern was specifically towards my race, and my kind of people, there just re-
ally wasn't like, maybe I’m assuming, like bilingual individuals to help out and just be able to 
help those class of women, like me. I guess what I’m just saying is I found myself being in like, 
a dark hole, not being able to have those resources for myself.” She expressed that at times be-
cause she is Hispanic she did not feel seen or heard, and it would help if someone looked liked 
her, could represent  her. As far as representation, JK, had a similar story.  
 JK states she was told, “That within African American women that we naturally have 
denser breasts, so they have to do more of a 3D type mammogram to really get everything.” Her 
medical provider gave her that information. She was diagnosed with breast cancer at the age of 
30 years old, as previously mentioned.  
 DSM expresses the implications of clinical trials in the African American community, 
stating “But we think you should go through it just in case and I was like, no, not gone through 
it. Just get well in we'll put we'll study you. I said, Listen, I am not going to be a part of your 
study. I said, we have a history of this in our in our race of being people's guinea pigs directly. 
I'm like, I didn't want to say that the whole Tuskegee experiment, but that's another issue. I said, 
I'm not going I don't need to go through I'm not going through it. And so, then I wasn't comfort-
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able with her.” DSM stating the provider wanting her to try a chemotherapy, but her not feeling 
comfortable due to historical implications. She also states, “Stop using black women as lab ex-
periments. We are not here for your study purpose. Like, don't tell me to go through chemo be-
cause you want to see what my reaction is. Like, that's wretched.” BMD also talks about her 
Mexican culture.  
 BMD talks about her Mexican culture. “We will always think that is not going to happen 
to us. It’s like, we know people get sick, or whatever, but we always like, I think, as a Mexican 
person, we always think it is not going to happen to us because we're Mexican. And we can do 
everything. But that's wrong. Because this concept thing, breast cancer is real. And it can happen 
to anybody, like, no matter, like, how old are you? Or where are you from? Or if you're Mexican, 
or American or Asian, it doesn't matter. I mean, it can happen to any person.” BMD was 36 years 
old when she was diagnosed with breast cancer, as aforementioned.  
 As we learned in Chapter Two, distrust can occur in minority groups stemming from the 
past of the Tuskegee Experiment and Henrietta Lacks. There is documentation that at times mi-
nority groups may feel unheard or unsupported, or have to feel stronger than they need to be. 
This was also represented by the voices of the interviewees. These particular minority groups 
have cultural implications that could have an impact on the trajectory of early education, early 
diagnosis and treatment in breast cancer.   
Support 
The women also emphasize the importance of support in their cancer journey. There was not 
much information regarding support, from family, or within the body of the facilities, but that 
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plays a huge role in the survivorship of the breast cancer patients who are trying to make it 
through.  
 CR expresses the importance of having a cancer buddy. “I met a friend in chemo. So, she 
was triple negative as well. And we went through the same treatment. We became good friends 
and we were there for each other. That's what if I could tell somebody, find somebody, you know, 
that's going through the same thing as you so you guys can talk about it and be there for one an-
other because that really helps because nobody else knows what you're going through.” TD also 
had a similar experience.  
 TD states, “I did end up befriending someone [going through similar treatments]. There 
was something about her that, um, just stood out to me, and we've been friends ever since.” 
YMD had similar support in her close network.  
 YMD states, “I think a combination of faith a combination of family, love, my husband, 
my kids, especially the kids, you fight hard for them cause you're like, my kids, no one can take 
care of my kids the way I take care of my kids.” She was 35 years old when she was diagnosed 
with TNBC. YMD is Puerto Rican, a wife, a mother of three great children. Dealing with han-
dling the family, and working is a lot to handle.  
Returning to Work / How Cancer is Viewed 
MC expressed her frustrations with returning to work and the whole concept of how others view 
cancer. 
 MC expressed, “And so I feel like treating all cancer like it the same way is such an unre-
alistic way to go about it; I feel like as a whole, the outlook towards cancer is old”. It seems like 
we all need to be educated or re-educated regarding the outlook on cancer, and how breast cancer 
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patients feel because not everyone feels the same, therefore, not every woman should be treated 
the same. While there was not literature stating this thought, it was significant to note. Addition-
ally, the women expressed the need for basic and extensive education.  
Education 
The women also expressed the importance of education before diagnosis, during and after. 
 CP stated, “Prior to the diagnosis, it would have been good to know about cancer, like I 
felt like I didn’t know a lot”. “I think that maybe if I or somebody educated me a little bit more 
about, risk factors and things like that, or if I read it, that would be good enough.” Additionally, 
MW also expressed the importance of education. 
 MW expresses the importance of education and family history, she states, “Education is 
important, know your family history.” JamRiv also talked about being educated about family his-
tory. 
 JamRiv speaks about knowing family history, “I think um, you know, it's just really im-
portant to know your family history and ask questions know, like, not just what they died from, 
but what they were diagnosed before. So, you know, some people now that I'm involved with 
advocacy, they think like that family member died of lung cancer or brain cancer, when come to 
find out it originated someplace outside. I think that's really, important. To understand and to, 
you know, if you have any of that cancer history in your family, start getting screened 10 years 
prior to that diagnosis, whether if it was on your mom's side or your dad's side.” This all stems 
from guidelines and recommendations.  
 We learned in Chapter Two that family cancer history is very important. It is important 
for the women to know who in their family had or has cancer, at what age they were diagnosed, 
  !67
and what type of cancer he or she had or has. This type information determines the risk or likeli-
hood of the woman being diagnosed with cancer. This information will also allow the woman to 
meet with a genetic counselor, start the process of genetic testing, and possibly, starting the 
screening process 10 years earlier than when the close relative was diagnosed with cancer. 
Guidelines and Recommendations 
The women also had some insight regarding policy implementation, guidelines and recommen-
dations.  
 MW expressing concern with the guidelines and recommendations, “But what made it 40 
years old?” Feeling frustrated over the number the is set for insurance to cover women to starting 
having annual mammograms. CW also states also another guideline recommendation frustration. 
 CW states. “The one thing that I will say during the mammogram process, I had actually 
not had it the year before, because I was advised that I could wait two years.” YMD, also states 
her frustrations.  
 YMD states, “I know that they say mammograms, you're not supposed to get them till 
you're 40 and blah, blah, blah. I just feel like they should definitely have that, like, you get a pap 
smear, then I feel like you should just get a mammogram because potentially I could have found 
this years ago, they say that breast cancer is dormant, not dormant, it's growing. But before you 
find a lump, it's been in you for two to five years. Oh, imagine just getting it early, a mammo-
gram or even an ultrasound or something, something that they can put you in through that just 
checks you know, even if it's every five years, five years is better than waiting till you're 40. You 
know, or right after you have kids, like, you know, I don't know, I just feel like they need to do a 
better job with that. Because 40 like, look how many people get breast cancer so early, you know, 
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and a lot of young people have cancer.” These findings are not consistent with the literature that I 
presented in Chapter Two because so many women are diagnosed with breast cancer prior to 40 
years old.  
 We learned in Chapter Two, that The U.S. Preventive Services Task Force (USPSTF) 
found there was no difference in risk of women dying from breast cancer from the ages of 40  to 
49 who had mammograms regularly, and if there was a difference, they found the difference to 
be very small (Susan G. Komen, 2020). This is where the age 40 stems from. The National Com-
prehensive Cancer Network (NCCN) agrees with the age, as well as The American Cancer Soci-
ety (ACS). Unfortunately, the guidelines recommendations need to change so that women who 
are younger than 40 years old can have insured mammograms regardless of their family history, 
genetics, or other factors; because they too can also be diagnosed with breast cancer.  
Insurance/Money Making 
There was also concern regarding insurance coverage, and the concept of hospitals simply mak-
ing money off the patients during the time of their treatments.  
 SFR expressed, “I can't believe that you're treating me like I was just I don’t know. It felt 
like it was about money at that point, and I know it is a business. But at that point, it wasn't about 
my treatment. It wasn't about my care.” MW also expressed her insurance coverage at the time. 
 MW stated, “One year went to like $5,000 per person, with I think it was like a $8, 000 
collected deductible.” She is expressing what she went through with her insurance through her 
cancer treatments.  
 CR was unable to freeze her eggs due to the cost. “And then it came back like through 
like my insurance, a paper saying that they weren't paying for it. And it was like $6,000. So, I'm 
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like, um, yeah, and I'm not paying.” CR was unable to freeze her eggs because she did not have 
the money to do so. Not realizing that there are so many costly elements that are associated be-
fore, after and during cancer treatments.  
 CR mentions, “I feel like people look at everybody as a number. Honestly, and I think it's 
all about money. But I think the main thing is everybody is just too busy.” JamRiv also had an-
other perspective about insurance regarding how she could have paid a lot more. She is very 
thankful for her insurance coverage.  
 JamRiv talks about insurance coverage in the grand scheme of things. She states, “Some-
times, you know, scans sometimes or follow up tests and things like that and procedures, the 
highest I think was maybe $500 or $800 for a copay, but in the grand scheme of things, you 
know, it's much, much more expensive when you see the full bill.” Also the concept of not hav-
ing insurance coverage upfront, and waiting until it happens. 
 TD explains how she felt her lump but waited to seek help until she had medical instance. 
“I felt the lump in the summer. I just started a new job. Just so I yeah, I was waiting for medical 
coverage. I've been working all my life. So, I'm not thinking Medicaid at this point when I was 
laid off [to get screened earlier].” Or the concept of thinking medical providers just wanting to 
use the “good insurance” to rack up a bill.  
  JK expresses her providers wanting to perform further testing. “You're not poking me no 
more, because I started to feel like a pin cushion. And then I told him I'm like, looking at my in-
surance. You see, I have good insurance. So, you want to order every test under the sun.” 
 JK also stated, “They [her insurance] denied me of a PET scan. They were saying, you’ve 
had the MRI, the CAT scans. And a PET scan is basically just a more invasive CAT scan and 
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they were like, well, if you just had the CAT scan a week ago, you don't need the PET scan. And 
I was okay with them denying that.” There are times insurance denies claims, but in this case JK 
was okay with that because she already had a previous scan. There were times the women did 
have insurance, but there was other times, the women did not have insurance.  
 BMD did not have medical insurance, so she had to wait to be seen in a clinic. She states, 
“They always so busy, you know, because they help people that don't have insurance. And they 
have a wait-list. You know, it's not like, as soon as you call, you're going to have an appointment. 
You have to wait.” While it is apparent, insurance is not technically needed to receive screening, 
or care and treatment, when the woman does not have insurance, she waits longer to receive 
help. 
 JR when speaking about Medicaid insurance, she states, “I applied for Medicaid, and I 
was approved for the Medicaid. But once I got to Medicaid, I was limited to only my state of 
treatment. I couldn't really go anywhere else, because everything had to be pre-approved. And I 
found that the doctors didn't really want to go through all that. I mean, it is kind of upsetting be-
cause it's like, you want other choices, but because I live in Delaware, it's not many choices of 
where I can go. So, I found that with this state insurance, you're very limited to where you can 
go, especially in a smaller state. Whereas if I live, like nearby in Pennsylvania, it's better. I'm 
sure if I had state insurance there. It would be better because it's so many different doctors, 
providers there.” This is the frustration of having state insurance because you are confined to 
only your state to receive health care, unless you want to pay out-of-pocket costs and copays.  
 What we learned in Chapter Two is that the importance of health insurance is for ensuring 
positive healthy behaviors such as screening such as mammograms, and other diagnostic tools 
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(Shakib, et. al., 2019, p. 1); and women who reported of having no health insurance coverage 
were less likely to have reported a recent mammogram test compared to women who had private 
health insurance (Shakib, S. H., et. al., 2019, p. 4). Typically, when women have insurance, they 
are more likely to get mammograms, versus women who are not insured as described above by 
the interviewees, and what issues they faced.  
 Some of the potential barriers that the women faced was due to family responsibility and 
taking care of their families. Some of the women were the primary care giver and needed to help 
their families. Other women needed to wait to be insured by their employer or needed assistance 
applying for governmental help. Other potential barriers include the women not prioritizing 
themselves, and not being educated about breast cancer and healthy living and eating. Depending 
upon the woman’s life other barriers included support and cultural implications. One of the big-
gest barriers is the recommendations and guidelines. Many of the women were told they were 
“too young” because there is a thought in minds that women can only get cancer at a certain age, 
therefore screenings may not be needed; though this information is false. The women that I in-
terviewed were not “too young” for cancer, and therefore, the guideline recommendations would 
benefit from being modified so that women, regardless of their age, could receive adequate in-
sured screening when needed.  
Reflection 
 The 21 women that I interviewed all came from various walks of life, but they all had 
certain variables in common, they were all younger than 50 years old when they were diagnosed, 
they are all women, and they all agree that early detection is what save their lives. Most of the 
women self-palpated their masses, and even when they might have been told they were “too 
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young” to have breast cancer, they advocated for themselves. These women had their husbands, 
children, family, friends, and medical staff support them. Though every story is different, the 
commonality is early detection—earlier than 40 years of age, and not having women skip a year 
just because of a previous clear mammogram. The other implication is what type of screening 
tool should be used when diagnosing young women with dense breasts; and how can providers 
get insurance companies on board to pay for more detailed screening, such as an MRI.  
Public Policy Recommendations and Developing Theories 
 The Affordable Care Act (ACA) requires most insurance companies to cover mammo-
grams, every one to two years, at little to no out-of-pocket cost to women who are between the 
ages of 40-74 years of age. There are programs and grants that assist those who do not have in-
surance, and need mammograms. Additionally, public policy implications of this study in general 
and specifically with respect to the federal health reform is simple, if a greater scientific consen-
sus were to be reached regarding the more appropriate screening frequencies for women of dif-
ference ages, policies could be amended accordingly (Bitler & Carpenter 2016, p. 21). Through 
the development and implementation of health policy, diagnostic 3D mammogram screening at 
little to no out-of-pocket cost could be mandated and would prevent potential barriers or gaps to 
women receiving care and treatment. The role of the insurance and insurance companies should 
be equitable and ethical to the women concerned about their breast health, regardless of the 
woman’s age.  
 The ethnographic research that took place would suggest that  coverage of mammograms 
through the Affordable Care Act should extend the to women in their twenties. Though there is 
limitation in interviewing 21 women, the importance is the age of their diagnosis and how and 
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why policy should be extended to them. Offering equality is no longer justified, equity is now the 
standard of care in terms of due process. Many of the women agreed that the recommended age 
should be lowered. The women thought that 40 years old should not be a standard number, but 
when a woman has a problem in her breast, it should be addressed; and it should be backed by 
policy, and covered by insurance, regardless of her age.  
 Universal healthcare could potentially aid in breast cancer prevention and catching breast 
cancer early or in its infancy. The World Health Organization (WHO) defines universal health-
care as “ensuring that all people have access to needed health services (including prevention, 
promotion, treatment, rehabilitation and palliation) of sufficient quality to be effective while also 
ensuring that the use of these services does not expose the user the financial hardship” (Zieff, 
Kerr, Moore & Stoner, 2020, p. 1). This was closely the goal of the Affordable Care Act (ACA), 
to ensure everyone has healthcare, and that there are preventative measures in place. Knowing 
the arguments against universal healthcare such as raising taxes, longer patient wait times, and 
big governmental interference. For the sake of this qualitative dissertation, we will focus on the 
benefits of such components of universal healthcare such as: reducing the vast health disparities 
that exist between differing socioeconomic status (SES) segments of the population and increas-
ing opportunities for preventive health initiatives (Zieff, et. al., 2020, p. 1). This will help close 
the gap between younger women being diagnosed with breast cancer.  Having a low SES is asso-
ciated with many unfavorable health determinants, such as limited access to quality health insur-
ance which can impact health outcomes and life expectancies (Zieff, et. al., 2020, p. 2). There-
fore, it is said that those who are of that population are in most need of accessible, quality health 
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insurance (Zieff, et. al., 2020, p. 41). This particular group tends to be more unhealthy and unin-
sured, presumably.   
 Therefore, value-based care can be thought of as appropriate plan of action. For example, 
the ACA has worked with programs such as the Healthy People Initiative by targeting modifiable 
determinants of health including physical activity, obesity, and environmental quality (Zieff, et. 
al., 2020, p. 5). This aids in prevention and aids in money saving, as well as, saving lives. By 
getting women to exercise, and decrease their body mass index, decreasing their risk of develop-
ing such diseases such as breast cancer, as discussed in Chapter Two. 
 In terms of New Public Service (NPS), the medical providers should be committed to 
medical equity. New Public Service “urges that administrators focus on building public institu-
tions marked by integrity, and responsiveness that serve and empower citizens by integrating cit-
izen discourse and public interest into the decision-making process” (Denhardt, Denhardt, & 
Blanc, 2014, p. 400). From the interviews, the feedback is consistent with changing current pub-
lic policy. This is the citizen discourse, and what starts the decision-making based on the interests 
of those affected. “The primary role of the public servant is to help citizens articulate and meet 
their interests rather than to attempt to control or steer society in new directions” (Denhardt, 
Denhardt, & Blanc, 2014, p. 400). This should be the goal of the government officials. The need 
of the people is to be able to seek an insured mammogram when medically necessary regardless 
of age.  
 That meets the interests of the people. “Public administrators must make the creation of a 
collective, shared notion of the public interest paramount” (Denhardt, Denhardt, & Blanc, 2014, 
p. 400). What is paramount is that statistically, women younger than 40 years old are being diag-
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nosed with breast cancer. Therefore, it is the duty of the people to have the mammogram age 
lowered. More poignantly, “Policies and programs to meet public needs can be most effectively 
and responsibly achieved through collective efforts and collaborative processes” (Denhardt, 
Denhardt, & Blanc, 2014, p. 400). With the help of patients, medical providers, medical staff, 
insurance companies, and policymakers, the work can begin to make mammograms equitable for 
all women. “The public interest is the results of a dialogue about shared values rather than the 
aggregation of individual interests” (Denhardt, Denhardt, & Blanc, 2014, p. 400). This is what 
this qualitative dissertation did. It is the voice of shared opinions, thoughts, and beliefs of breasts 
cancer survivors, who shared some commonalities.  
 Though they were all different and unique, a common consensus was they agreed the 
mammogram age should be lowered, and they all agreed they were diagnosed at a young age. 
“Public servants must be attentive to more than the market” (Denhardt, Denhardt, & Blanc, 2014, 
p. 400). There is so much more than money, and how much everything costs. Though that is ab-
solutely important, and should be considered, lives are so much more important. “Public organi-
zations and the networks in which they participate are more likely to be successful in the long 
run if they are operated through processes of collaboration and shared leadership based on a re-
spect for all people” (Denhardt, Denhardt, & Blanc, 2014, p. 400). The ultimate goal is equity for 
all women, so that everyones lives can be saved, regardless of age, or insurance coverage. Lastly, 
“The public interest is better advanced by public servants and citizens committed to making 
meaningful contributions to society” (Denhardt, Denhardt, & Blanc, 2014, p. 400). It is much 
better to help others in many ways (such as share their stories), so that policy makers, medical 
providers, and others can see the impact that such medical practices and policies are having on 
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real women’s lives. Some components of Universal healthcare can close the health disparity 
gaps, and save many lives.  
 Equity in health policy and healthcare coverage should include aspects of participatory 
decision-making, advocacy from both the patient and the provider and patient-orientation. The 
main theories are community-owned government, customer-driven government, and anticipatory 
government. The goal of the community-owned government is to empower the community with 
the necessary tools to learn about breast cancer and advocacy to speak up for themselves when 
something is out of their normal. Education will be a driving factor in developing advocacy skills 
and building knowledge related to health conditions and treatment options. Customer-driven 
government is simply meeting the needs of the customer, or in this case, the patients. The pur-
pose of this governmental insertion will garnish funding and therefore guarantee implementation. 
Lastly, anticipatory government may focus on trying to prevent the issue of breast cancer from 
arising at all; perhaps through education, scientific research, clinical trials, and policy change. 
From an education perspective, preventative measures will be allocated to teach the community 
strategies to decrease their breast cancer risk. Additionally, scientific research will propel clinical 
trials— and policies can be amended, changed and created to meet the needs of the people; such 
as lowering the mammogram age from 40 years old.  
Possible Gaps 
 The possibility of gaps from the breast cancer diagnosis to treatment can stem from 
screening age, health insurance, financial responsibility, familial responsibility, education/
women’s awareness, and distrust. MC, CP, CR, LynMit, DD, DSM were all told they were “too 
young” too have breast cancer by a medical provider, and though necessary steps were eventual-
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ly taken to diagnosis their breast cancers, had they have waited—they may have not been here to 
tell their stories. Similarly, the screening age recommendation starts at the age of 40 years old, 
but these women other than one were all less than 40 years old prior to their diagnosis. CW was 
told after a clear mammogram that she could wait two years to have a repeat screening. She was 
later diagnosed with breast cancer. The potential gap is age and how young women can be hin-
dered from receiving mammography’s and preventive screenings. Another potential gap is health 
insurance and financial responsibility.  
 BMD and MV did not have insurance before their diagnosis and therefore had to wait 
once they discovered their lumps to obtain some sort of insurance help. BMD had a difficult time 
because even when she sought help, the free clinic was booked to capacity, so she had to wait. 
TD and JamRiv both waited a period until they had medical insurance from their jobs to seek 
help. JamRiv also had to take on the familial responsibility of being the breadwinner of her fami-
ly and the insurance carrier; therefore, not working the entire time of treatments. The potential 
gap in terms of insurance coverage and familial responsibility is that it can hinder when women 
get seen for their breast health. BMD and MV had to wait for a period because they had no med-
ical insurance. TD and JamRiv had to wait because they started new jobs and needed to wait un-
til the probationary period was over. In terms of family responsibly the women put their families 
first and focus on themselves last. BMD and JamRiv actively took care of their families before 
self-prioritizing themselves. All the women needed to be truly aware and educated about the top-
ic of breast cancer. 
 The topic regarding breast health and breast cancer is a potential gap. The women seem 
to not understand the true gravity of it, and that may be due to providers downplaying because of 
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their age. CP, MW, CW, KB mentioned that they wish they knew more about breast cancer, 
breast health, and the overall process from diagnosis to treatment and everything in-between. 
CW mentioned it would be helpful to know what questions to ask because everything was so 
new to her, she did not know what she needed to know or what to ask. Questions are especially 
important due to mistrust. 
 TD and DSM both mentioned cultural differences in which medical providers should be 
cognizant of because it can create a gap in terms of screening, diagnosis and treatment. DSM es-
pecially mentioned the Tuskegee experiment and how that distrust in the medical community still 
holds true today within the culture to some degree. That potential gap should be known so a 
space of trust can be created between patient and provider.  
Patient-Provider Relationship 
 Patients need to be able to trust their medical providers. Medical providers need to be 
able to trust that the patients know and understand their body. When a patient presents to the 
medical provider, there needs to be trust between the two parties to solve the issue. The theory of 
attachment rings true within the patient-provider relationship. Attachment theory and attachment 
styles can be defined as working models or patterns of how individuals’ function and interact 
within significant relationships (Kelly, E. P., Tsilimigras, D. I., Hyer, J. M., &; Pawlik, T. M., 
2019, p. 102). The attachment theory formally was based from mother and infant, and how the 
infant looks to the mother for nutrients and guidance. The same is true in the patient-provider 
theory. The infant or patient looks to the mother or provider for assistance because the provider is 
the one who can help. Attachment behaviors are often triggered when an individual attempt to 
seek comfort and security to cope with triggering stressful situations such as a cancer diagnosis 
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(Kelly, E. P., et. al., 2019, p. 103). Knowing this the provider can be aware of the role that he or 
she plays in the patient’s life and what type of reaction the patient may have, and why they have 
that reaction.  
 Both parties need to somewhat be attached or understand/trust one another to a level of 
completion and comfort. Especially in the context of patient-provider relationship relating to 
breast cancer—the cancer diagnosis is very emotional and nuanced; it is a long journey and the 
patients are with their providers for a long time (Kelly, E. P., et. al., 2019, p. 101). That reason 
alone, the relationship must be trustworthy and attached. It is imperative that providers are sensi-
tive to the topic of breast cancer, and the topic of narrative medicine. Secure attachments within 
the patient-provider relationship have been associated with better treatment outcomes (Kelly, E. 
P., et. al., 2019, p. 102). Insecure attachments relate to negative treatment outcomes and patient-
provider relations (Kelly, E. P., et. al., 2019, p. 102). 
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Chapter Five: Conclusion 
 The significance of this qualitative dissertation is to determine: What are women’s early 
experiences in their cancer diagnosis; and are there any components serving as barriers to their 
treatment? Public policy refers that states are mandated to pay for women’s mammograms at the 
age of 40 years old and older, annually (can vary), per The American Cancer Society (ACS), The 
National Comprehensive Cancer Network (NCCN), and The U.S. Preventive Services Task 
Force (USPSTF); therefore, increasing mammogram utilization. The issue is there needs to be an 
addendum to the guidelines for women less than 40 years of age due to certain risk factors, such 
as, age, family cancer history, genes, menstrual status, oral contraceptive use, birth history, lack 
of education, age of first and last birth, and maternal smoking.  
 This qualitative dissertation aimed to research if there were gaps, and if so, how to lessen 
them by way of women’s awareness, patient-provider relationship/interaction, prevent possible 
barriers, amend recommendations, insurance protocols, and screening guidelines. 
Major Findings and Recommendations 
 There were many themes that emerged from the interviews such as women being “too 
young to get breast cancer,” familial responsibility, prioritizing self, cultural implications, sup-
port, self-examinations, patient-provider relationship, religion/spirituality, accurate/adequate 
screening tools (diagnosis tools), how cancer is viewed, education, guidelines and recommenda-
tions, earlier diagnosis, privacy, insurance/money making, and genetics. The themes that are 
most pressing are race and age, diagnostic tools, patient-provider relationship, the role of public 
policy and insurance coverage.  
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 Black women have the highest breast cancer incidence rate before age 40 years and are 
most likely to die from breast cancer at every age (Desantis et al., 2019). Public policy/health 
care insurance policy should reflect this health disparity in cancer incidence and mortality; Black 
women under the age of 40 should be screened very closely. My interviews reinforced that al-
though Black women have been found to be disparately impacted, women of all races are devel-
oping breast cancer before the age of 40. Based on these interviews, I recommend that although 
Black women should have additional screening and health care options, women of other races 
should not be excluded.  
 Other findings were discussed, such as the topic of diagnostic tools and MRI utilization. 
A policy that could be updated to address this is using MRIs as the first line of defense, if a 
woman is known to have dense breasts; or after a mammogram is performed, and it is seen that 
her breasts are dense, a MRI should be performed. MRIs are more expensive upfront, from a 
cost-effectiveness point-of-view; but from a lifesaving perspective, it is priceless.  Therefore, 
tighter healthcare administration need to be performed. For example, many women fill out pa-
perwork about family history, but nothing is usually done about it until the woman is diagnosed. 
In terms of healthcare administration, there should be a system in place to alert medical person-
nel if a women has a close family cancer history, and other key components that will aid in de-
tection, and possible prevention. Bitler and Carpenter would agree in their concluding assess-
ment that, “If a greater scientific consensus were to be reached regarding the most appropriate 
screening frequencies for women of different ages, policies could be amended 
accordingly.” (Bitler and Carpenter, 2016, p. 21). Additionally, healthcare reform increases 
mammography screening utilization, and prevents no deductibles for preventative care. This will 
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change and help with inequities. The inequities of women not receiving adequate healthcare due 
to their age, or insurance coverage. By removing those barriers, eliminates the gaps, and provides 
equitable healthcare for the population that is need of mammograms. In addition, the role of the 
patient-provider relationship is imperative. 
 The theme of the patient-provider relationship emerged frequently. The approach of the 
paternalistic model emerged at times. This approach emerges when the doctor drives the trajecto-
ry of the patients care. The majority of the time, what was found, the patient, and the provider 
were found to be involved in the deliberate approach, as is described in Chapter Two. While the 
woman primarily advocated for herself, the medical provider also agreed with their medical ex-
pertise to take certain steps toward finding common ground. Interestingly, women who advocat-
ed for themselves, and the providers who took a paternalistic approach all came to the same con-
clusion, around the same time. The difference is the women who were advocates, pushed through 
medical barriers, compared to the women who listened to their providers; who for example were 
told to wait because they were “too young” for breast cancer. Public policy could create a more 
equitable experience so that these differences are not an influential of a driver of patient screen-
ing outcomes by promoting research in language and communication tools. This would eliminate 
barriers between any approach and women receiving appropriate care.  
 The role of public policy in promoting equity in access to early screenings and often giv-
en the conceptual framework for the patient-provider relationship provided by Kelly (2019) re-
sult in understanding, researching, and concluding from the patients behaviors and needs. This is 
a huge component that is missed. Patients behaviors are based in many respects to what they 
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need, from a macro-level or mirco-level. Women need covered mammograms regardless of their 
age. They also need providers that are on the same page with them. All of these components de-
termines the success and trajectory of treatment and prognosis, in some respects. Perhaps public 
policy should be informed by the attachment theory in order to improve equity in access to 
screening for all women early and often. That looks like mandating the early breast health educa-
tion. Public policy could be improved to account for insecure or avoidant attachment types and 
the ways that patient-provider relationships are impeded by that. This way women who are in 
need of the paternalistic approach receives the same care as those who are more deliberate.  
 In Chapter Four, there were women who did not seek medical attention immediately due 
to lack of insurance, starting a job and waiting for the insurance to kick in, and simply needing to 
prioritize their families first. There needs to be an employment related policy that could help 
women to feel that their jobs are protected or that they are entitled to go to appointments. Many 
women under treatment would feel rushed because they had to get back to work, or needed to 
know exactly when they were finished all of their treatments because they needed to return to 
work. The entire mindset was on work, and not on themselves, healing their bodies. There is 
FMLA and disability, but that is only covered for 12 weeks, unpaid, in the calendar year. It is 
very difficult for patients to tolerate that. Treatments can last longer, and the remnants of the 
treatments can last even longer than that.  Sick leave policies for different kinds of jobs/employ-
ers impact their preventative health care behaviors depending on the job services such as nannies 
and home-aid care. Public policy should be implemented so the patients are receiving an ade-
quate percentage of their income, and are able to recuperate and recover during and after treat-
ments, when needed.  
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 In terms of public policy, it is important to bring the themes of the interview and policy in 
full circle. Public policy recommends all women starting at the age of 40 years old receive a 
screening mammogram. Due to this policy, states in the United States of America, are mandated 
to cover a women’s annual mammogram whether the woman has insurance or not. If the woman 
does not have insurance, hospitals and clinics, have funding to provide free screenings. If the 
woman has a clear mammogram, it is her decision to wait another one to two years for a repeat 
screening. The issue with this policy is that women under the age of 40 are being diagnosed with 
breast cancer. Now, there are some caveats from younger women receiving insured mammogra-
phy screening—if the woman has a family history of certain cancers, has been exposed to radia-
tion, is a BRCA1 or BRCA2 carrier or other predetermined genetics, and alike. While this is a 
great loophole, the problem is it is not equitable for the women who do not fit into any of these 
categories, but have been diagnosed with breast cancer. The goal in public policy is to make 
policies that are equitable and not based on equality.  
 Equality gives everyone the same opportunity. For this policy, the blanket statement is if 
you are 40 years older, unless otherwise noted, you can receive an insured mammogram. Equity 
gives women who may not have the same resources, or education, alike the same opportunities, 
every other woman would receive. For example, the policy could change to: Women who have 
an issue with their breasts are able to receive an insured 3D mammography. If any of those 
women are high risk, they should receive either a 3D mammogram, including an ultrasound and 
maybe a breast MRI. There needs to be a shift in equality policy to equity policy. Some compo-
nents of Universal healthcare can be implemented to help close the disparity gap and make 
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healthcare more equitable. Also components of the New Public Service (NPS) would help aid in 
such a plight.  
Limitations and Directions for Future Research  
 The limitations of this qualitative dissertation stems from the amount of breast cancer 
survivors that were interviewed. The number of 21 participants limits the amount pertinent and 
sound information. Another approach that could have been utilized is through a case study ap-
proach where each participant or one participant and their story would be carefully and succinct-
ly analyzed for the sake of policy reform and recommendation.  
 For future research hospitals and clinics could be involved in research to determine how 
many women under the age of 40 are being diagnosed with breast cancer and what are their early 
experiences. Do they have a family cancer history? If yes, did they know their family cancer his-
tory before their diagnosis? Did they self-palpate their mass? Were they told they were “too 
young” for cancer? Also, a survey could be conducted to breast cancer survivors following the 
themes that arose in the interviews. What are their thoughts on genetics? If they are African 
American, do they know what country they come from in Africa? Do they have dense breasts? 
Did they receive a 3D mammogram, and did it show malignancy the first time of screening? Did 
they have a follow-up breast MRI for further detection? 
Concluding Thoughts 
 I recommend young women feel their breasts. I recommend that medical providers listen 
to their young patients when they are present with a problem. I recommend that because younger 
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women have dense breast tissue and when 3D mammography is not clear, breast MRI is the 
screening line of defense. I also recommend that women are educated regarding breast health and 
finding ways on how to decrease their risks of developing breast cancer. Policy reform needs to 
change the line of defense of breast screening and the age the women are screened.  
 Currently the recommendations states screening to being at the age of 40 years old unless 
the woman is at high risk, such as has a family history of cancer. The reform needs to incorporate 
women who are at average risk, and those who are less than 40 years old because they are being 
neglected. I recommend that women are educated about breast health and preventative measures 
regarding breast cancer. Women also need to have the option of receiving 3D mammography re-
gardless of their age if they seek help to their medical provider regarding a suspicious finding. If 
the palpable finding is not clearly defined, then I recommend an ultrasound, but ideally a breast 
MRI for clarity and distinction. Too many of the women that were interviewed shared that it was 
not until they had their breast MRI that their cancer was clearly identified. Mammograms detect 
breast cancer, and if it cannot perform its job, another route must be utilized. 
 Additionally, insurance companies should not dictate the coverage of a woman’s suspi-
cious finding. If a woman finds that something is wrong with her breast, regardless of her age, or 
insurance status, she should have it checked out. The goal in policy reform is to make a differ-
ence, and in making the difference of changing the mammography age, or diagnostic tools, and 
determining insurance coverage will ultimately save millions of women’s lives and make the dif-
ference. It is paramount that education and preventative measures are implemented, but without 
the support of reform, change will only go so far. 
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Existing policy states that women are recommended to have mammography screening 
annually starting at the age of 40 years old, unless at high risk; which includes having a family 
history of certain cancers such as breast and ovarian. I seek to revise that policy to state that 
women should have annual mammograms starting at the age of 30 years old as mandated. Addi-
tionally, for women who were diagnosed with breast cancer prior to the age of 30 years old, and 
palpated their mass, policy should be revised to allow medical insurance to cover their screening 
mammography, ultrasound and/or MRI. The existing programmatic changes that should be made 
include medical insurance coverage for the women who are not 30 years old or older, and either 
pay a small copay or are covered to received proper screening. 
There are many programs that should implemented and funded federally and locally to 
help decrease the risk of women developing breast cancer. There needs to be more educational 
resources to educate women who to decrease their risk, such as: eating healthier, exercising, not 
smoking, reducing the amount of alcohol and sugary drinks, and maintaining a healthy body 
weight (Helen F. Graham Cancer Center Advisory Board, 2020). These types of resources are 
monumental in the fight and knowledge against breast cancer. In the interviews, it was noted that 
some women did not know much about breast cancer prior to their diagnosis, and would have 
liked to understand ways to decrease their risk. Some felt, if they were educated prior to their 
diagnosis, maybe they would have not been diagnosed.  
Additionally, another program should be in place for women who do not have insurance 
and are uncertain if they would be able to receive diagnostic screening. Educating young women, 
and all women alike, the risks of breast cancer, how to feel on their breasts and look at their 
breasts, focus on their bodies, understand insurance (and dispel myths), give them adequate ques-
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tions when meeting with their medical provider (and how to make their visit useful and success-
ful), understand the importance of knowing their family cancer history, the differences between 
diagnostic tools (mammography, ultrasound, MRI), treatment options, support groups, genetics, 
family and cultural support, language support and host of other educational resources to help 
women successful to prevent cancer and in their fight of breast cancer. Education is the corner-
stone of the success in breast cancer prevention, and treatment.  
 Women’s early experiences were paramount. They experienced some barriers, but 
through advocacy and patient-provider relationship they were able to share their stories and help 
others in their journey of care. Therefore, I remember, love, value, and admire all these women 
who have gone before me, and who are in the present who have battled breast cancer with every 
bit of dignity, grace and strength they had in them. This qualitative dissertation sought out barri-
ers and gaps to prevent deaths in women, and especially women who are younger than 40 years 
old. The point is to strengthen and awaken the relationship between the patient and the medical 
provider, so that the trajectory of treatments is lifesaving, not life ending. It is important to catch 
breast cancer in its’ infancy through screening and detection, and when this is done, regardless of 
the risks, it can be maintained just like other diseases.  
 Therefore, I recommend for the mammography screening to be equitable and fair. Women 
who are 30 years old should be able to have diagnostic mammography screenings, and covered. 
Women who are not 30 years old, but confide in their medical providers about a breast issue, 
should also be able to have mammography screenings, covered, regardless of her age and insur-
ance status. The goal of public policy is to benefit the whole, and to do that, equity must be im-
plemented, and fairness.  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[B] Consent Guide 
 Project Title: Federal Health Reform: Breast Cancer Outcomes 
Investigator(s): Nia Bailey, M.A.Ed., RT(T); Kristen Crossney, PhD 
Project Overview: 
Participation in this research project is voluntary and is being done by Nia Bailey, M.A.Ed., 
RT(T) as part of her Doctoral Dissertation to determine what are women’s early experiences with 
their medical providers who have been diagnosed with breast cancer? Also, to determine if there 
are components of their early experiences functioning as barriers to getting treatment? If you 
would like to take part, West Chester University requires that you agree and sign this consent 
form. 
You may ask Nia Bailey, M.A.Ed., RT(T) any questions to help you understand this study. If you 
don’t want to be a part of this study, it won’t affect any services from West Chester University. If 
you choose to be a part of this study, you have the right to change your mind and stop being a 
part of the study at any time. 
1. What is the purpose of this study? 
o Determine what are women’s early experiences with their medical providers who 
have been diagnosed with breast cancer? Also, to determine if there are compo-
nents of their early experiences functioning as barriers to getting treatment? 
2. If you decide to be a part of this study, you will be asked to do the following: 
o Complete interview 
o This study will take about 45 minutes to 1 hour of your time. 
3. Are there any experimental medical treatments? 
o No 
4. Is there any risk to me? 
o Possible risks or sources of discomfort include of discomfort that are associated 
with this interview that can stem from the conversation regarding the topic of the 
participants breast cancer journey. The questions have the potential to stir other-
wise latent feelings that the participants had. If that were to occur, the interview 
may cease at any time. The participant has the right to decide not to want to pro-
ceed further in the interview process, and furthermore no longer giving consent 
for information. Additionally, resources to the American Cancer Society and Su-
san G. Komen are links that will be presented to the women, if they need as-
sistance. Additionally, a confidentiality breach will not occur on behalf of the re-
searcher. The researcher takes ethics, and the consent process very seriously, and 
in no way will break the agreement between researcher and participant 
o If you become upset and wish to speak with someone, you may speak with Amer-
ican Cancer Society and/or Susan G. Komen 
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o If you experience discomfort, you have the right to withdraw at any time. 
5. Is there any benefit to me? 
o Benefits to you may include: no direct benefit to participants. The participants 
may feel a sense of purpose being a part of research bigger than them that will 
contribute knowledge that might assist in providing recommendations for breast 
cancer treatment and policies in the future  
6. How will you protect my privacy? 
o The session will be recorded. 
o Each participant will be given a username (their initials, approximate age, and 
date the interview was conducted; for example, NB2706302020) and password 
for the meeting space. The patient has the option to not use video, if she does not 
feel comfortable with doing so. After the interview, the file will be saved under 
the patients initials and date of the meeting and transcribed by Otter. I will only 
send the audio portion of the Zoom interview through Otter for transcription, 
without the video component. Otter is a safe artificial intelligence (AI) service 
that transcribes dialogue. This is a safe and secure platform in which no other per-
son will have access to the interview but the researcher. 
o Your records will be private. Only Nia Bailey, M.A.Ed., RT(T), Kristen Crossney, 
PhD, and the IRB will have access to your name and responses. 
o Your name will not be used in any reports. 
o Records will be stored:  
▪ Password Protected File through Qualtrics 
o The names of the breast cancer patients will not be used. Their initials will be 
used instead. Also, as aforementioned, each participant will be given a username 
(their initials, approximate age, and date the interview was conducted; for exam-
ple, NB2706302020) and password for the meeting space. The audio file of the 
Zoom interview will only be sent to the Otter transcription company. The infor-
mation will be destructed 3 years after completion of the manuscript. The signed 
originals will of the informed consent forms will be stored through Qualtrics. Dr. 
Crossney and I, Nia Bailey, will be the only ones to have access to the consent 
documents and data. The data will be stored through Qualtrics and secured by 
measures of using a password that only we have access to. The participants ini-
tials and the date that they are being interviewed will be used. The computer will 
be stored at 9-3 Wilde Ave. Drexel Hill, PA 19026. 
o Records will be destroyed Three Years After Study Completion 
7. Do I get paid to take part in this study? 
o No 
8. Who do I contact in case of research related injury? 
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o For any questions with this study, contact: 
▪ Primary Investigator: Nia Bailey, M.A.Ed., RT(T) at 267-886-5471 or 
NB744036@wcupa.edu 
▪ Faculty Sponsor: Kristen Crossney, PhD at 610-430-5838 or 
kcrossney@wcupa.edu 
9. What will you do with my Identifiable Information/Biospecimens? 
o Not applicable. 
For any questions about your rights in this research study, contact the ORSP at 610-436-3557. 
I, _________________________________ (your name), have read this form and I understand 
the statements in this form. I know that if I am uncomfortable with this study, I can stop at any 
time. I know that it is not possible to know all possible risks in a study, and I think that reason-
able safety measures have been taken to decrease any risk. 
______________________________________________________ 
Subject/Participant Signature            Date:________________ 
_________________________________ 
Witness Signature                     Date:________________ 
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[C] Interview Guide 
Nia: Thank you again for taking the time to participate. Just a quick overview, the purpose of this 
interview is to understand your early experiences with your medical provider, and to see how 
that translated into treatment and diagnosis. Quickly, I want to confirm with a yes or no, that you 
have signed consent— and you understand at any point during the interview you have the right to 
not answer any question or stop the interview.  
Participant: [Insert Answer] 
Nia: Great! Let’s get started! 
Nia: What type of provider/doctor did you see before your diagnosis? GYN? Family medicine? 
Or did the doctor find your tumor during a routine visit? 
Participant: [Insert Answer]  
Nia: Did you feel that you had a problem (lump or pain) or did your doctor find a lump? 
Participant: [Insert Answer] 
Nia: What was your thought process? Did you have support? 
Participant: [Insert Answer] 
Nia: Ok, lead me on that journey from the moment of discovery. How long did it take you to get 
screened? 
Participant: [Insert Answer] 
Nia: What type of imaging did you get? Mammogram? Ultrasound? MRI?  
Participant: [Insert Answer] 
Nia: Do you have dense breasts? 
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Participant: [Insert Answer] 
Nia: What was your experience in those early conversations with your doctor? Did you have to 
wait to have a biopsy? 
Participant: [Insert Answer] 
Nia: When did you find out about your diagnosis? Do you remember that moment? Tell me about 
it. 
Participant: [Insert Answer] 
Nia: How old were you when you were diagnosed? 
Participant: [Insert Answer] 
Nia: Do you know what type and what stage of breast cancer you have/had? 
Participant: [Insert Answer] 
Nia: Did you choose to have a lumpectomy, or mastectomy? Why? If you had a mastectomy, did 
you choose to get implants? Why or why not? 
Participant: [Insert Answer] 
Nia: What was your course of treatment? 
Participant: [Insert Answer] 
Nia: Did you have genetic testing performed? If so, in what part of the process did you have this 
done? What were the results? 
Participant: [Insert Answer] 
Nia: Do you have a family history of cancer? At what age were they when they were diagnosed? 
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Participant: [Insert Answer] 
Nia: Did you know your family history prior to being diagnosed? 
Participant: [Insert Answer] 
Nia: Do you feel you lived a healthy life? Did you smoke prior to your diagnosis? If so, at what 
age? For how many years? 
Participant: [Insert Answer] 
Nia: Do you think clinical trial are important? Have you enrolled in one? Are you currently en-
rolled in one? Would you ever enroll in one? 
Participant: [Insert Answer] 
Nia: Do you have a religion? If so, has that helped you through your journey?  
Participant: [Insert Answer] 
Nia: Are you finished your cancer treatment journey? If no, what is next? 
Participant: [Insert Answer] 
Nia: Do you have children? Want children? Want more children? After diagnosis and treatment? 
Participant: [Insert Answer] 
Nia: If you have children, how old were you when you gave birth to your children? 
Participant: [Insert Answer] 
Nia: If you want children, did you freeze your eggs? Why or why not? Also, how long do you 
have to wait to start the childbearing process? 
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Participant: [Insert Answer] 
Nia: Have you ever been on birth control? For how long? 
Participant: [Insert Answer] 
Nia: How old was your mother when she birthed you? 
Participant: [Insert Answer] 
Nia: Did you have insurance prior to your diagnosis? Did you ever have to pay a copay or de-
ducible? Was it affordable? 
Participant: [Insert Answer] 
Nia: Has your insurance ever denied you of a procedure—specifically screening? Or type of 
screening? Was it due to your age? 
Participant: [Insert Answer] 
Nia: What was your occupation prior to your diagnosis?  
Participant: [Insert Answer] 
Nia: Did you work while going through treatment? Why or why not?  
Participant: [Insert Answer] 
Nia: What was your relationship status prior to your diagnosis? 
Participant: [Insert Answer] 
Nia: What would you wish was different about the early process? 
Participant: [Insert Answer] 
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Nia: Are you aware that depending on your family cancer history, and genetic testing, you could 
have received screening earlier in your life, according to policy guidelines? 
Participant: [Insert Answer] 
Nia: To wrap up, is there anything else you would like to share about your story? 
Participant: [Insert Answer] 
Nia: Thank you so much for allowing me to interview you about this sensitive time in your life. I 
look forward to highlighting in my dissertation your voice and why your life absolutely matters. 
Also, as aforementioned, please know that this interview in confidential, and will only be shared 
with Otter for transcription (with your initials) and for the purposes of my dissertation. Just a lit-
tle secret, my hope in this interview is to change screening tools and policy; which is why my 
research questions are: What are women’s early experiences with their medical providers who 
have been diagnosed with breast cancer? Are components of their early experiences functioning 
as barriers to getting treatment? My hope is that the answers to the questions will guide policy 
makers into a direction that is always patient centered. That shift will hopefully guide change in 
policy. Thanks again! 
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[D] Support Groups 
Susan G. Komen Philadelphia American Cancer Soci-
ety 
125 South 9th Street, Suite 202 
Philadelphia, PA 19107
N/A
Phone 215-238-8900/Fax 215-238-1419 1-800-227-2345
https://komenphiladelphia.org https://www.cancer.org 
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Every year starting at 
age 30 a mammogram, 
and depending on the 
woman’s provider, a 











Every year starting at 
age 30 a mammogram, 
and depending on the 
woman’s provider, a 






years old or 












Varies Under the 
age of 25, 
it is only 
recom-
mended 







For women between 
the ages of 25-29, it is 
recommended that 
every 6-12 months 
they have a clinical 
breast exam; every 
year have a breast MRI 
performed, and if an 




have a first 
degree relative 
with a BRCA 
1 or BRCA 2 
gene mutation, 
but personally 
not tested for 
those genes 
themselves







Mammograms to be 
performed starting at 
age 30 and encouraged 
to talk to their 
providers about genet-
ic testing before get-













have a clinical 
breast exam, 
starting 10 









Women who are 30 
years and older, it is 
recommended every 6-
12 month starting 10 
years after radiation 
treatment to have a 
clinical breast exam. A 
mammogram and 
breast MRI should be 
performed, every year 










syndrome or a 
TP53 gene 
mutation







age 20 or 












Every year should 
have a breast MRI, and 
if one is not available 
then a mammogram. 
Women 30 years old or 
older should have a 
clinical breast exam 
every 6-12 months and 
a mammogram and 






syndrome or a 
PTEN gene 
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breast MRI’s should 
happen every year 
starting at the age 
30-35 or 5-10 years 
before the age of the 
youngest breast cancer 









or NBN gene 
mutation






ing at age 
40
Mammograms should 
be had every year 
starting at age 40, and 
women should talk 
with their providers 
about breast MRI’s 
starting at age 40
CDH1 gene 
mutation







ing at age 
40 
Mammograms should 
be had every year 
starting at age 30, and 
women should talk 
with their providers 
about breast MRI’s 
starting at age 30. 
 NF1 gene 
mutation







ing at age 
40 
Mammograms should 
be had every year 
starting at age 30, and 
women should talk 
with their providers 
about breast MRI’s 

















ing at age 
40
Mammograms should 
be had every year 
starting at age 30, and 
women should talk 
with their providers 
about breast MRI’s 
starting at age 30
STK11 gene 
mutation 







ing at age 
40 
Mammograms should 
be had every year 
starting at age 40. 
Women with a 
personal histo-









Varies Varies 1-4 times 
a year for 





















ing at age 
40
Mammograms should 
be performed annually 
starting at age 40, and 
a talk with their health 
care provider is needed 
to determine is a breast 
MRI is necessary
Women ages 
35 and older 
with a 5-year 
risk of inva-
sive breast 
cancer of 1.7 
percent or 
higher












year starting at the age 
found to be at in-









Women with a 
greater than 
20 percent 




















be performed every 
year starting 10 years 
younger than the 
youngest breast cancer 
case in the family, but 
not before the age of 
30. A breast MRI 
should be performed 
every year starting 10 
years younger than the 
youngest breast cancer 
case in the family, but 
not before the age of 
25
If women 
have a first 
degree relative 
with a BRCA 
1 or BRCA 2 
gene mutation
Varies Varies N/A Encouraged to speak 
with their provider 
about the MRI, if they 















LCIS Varies Annual N/A Mammogram 
every year, and 
talk to with a 
provider about 




Varies Annual N/A Mammogram 
every year, and 
talk to with a 
provider about 





30 Annual N/A Mammogram 
and breast 
MRI every 
year starting at 
age 30 or the 
age recom-
mended by the 
provider 
has a first de-
gree relative 
with a BRCA1 
or 2 mutation 
but personally 
not tested for 
the gene muta-
tions
30 Annual N/A Mammogram 
and breast 
MRI every 
year starting at 
age 30 or the 
age recom-





30 Annual N/A Mammogram 
and breast 
MRI every 
year starting at 
age 30 or the 
age recom-







30 Annual N/A Mammogram 
and breast 
MRI every 
year starting at 
age 30 or the 
age recom-
mended by the 
provider 
Has a first de-
gree relative 
with one of 
these syn-
dromes
30 Annual N/A Mammogram 
and breast 
MRI every 
year starting at 
age 30 or the 
age recom-
mended by the 
provider 





Has a first de-
gree relative 
with one of 
these syn-
dromes
30 Annual N/A Mammogram 
and breast 
MRI every 
year starting at 
age 30 or the 
age recom-





tween the ages 
of 10-30
30 Annual N/A Mammogram 
and breast 
MRI every 
year starting at 
age 30 or the 
age recom-
mended by the 
provider 
Personal histo-
ry of Breast 
cancer includ-
ing DCIS 
Annual N/A Every year 
should have a 
mammogram 
and a breast 





Annual N/A Every year 
should have a 
mammogram 
and a breast 
MRI should be 
consulted with 
a provider












30 Annual N/A Mammogram 
and breast 
MRI every 
year starting at 
age 30 or the 
age recom-
mended by the 
provider
Problem Age Frequency Clinical 
Breast Exam
Diagnostic 
Tool
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